



Review

Progress on the development of therapeutics against West Nile virus

Michael S. Diamond*

Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine,
660 South Euclid Avenue, Box 8051, St. Louis, MO, United States

ARTICLE INFO

Article history:

Received 7 May 2009

Accepted 27 May 2009

Keywords:

Therapy
West Nile virus
Antiviral
Antibody
Pathogenesis

ABSTRACT

A decade has passed since the appearance of West Nile virus (WNV) in humans in the Western Hemisphere in New York City. During this interval, WNV spread inexorably throughout North and South America and caused millions of infections ranging from a sub-clinical illness, to a self-limiting febrile syndrome or lethal neuroinvasive disease. Its entry into the United States triggered intensive research into the basic biology of WNV and the elements that comprise a protective host immune response. Although no therapy is currently approved for use in humans, several strategies are being pursued to develop effective prophylaxis and treatments. This review describes the current state of knowledge on epidemiology, clinical presentation, pathogenesis, and immunobiology of WNV infection, and highlights progress toward an effective therapy.

© 2009 Elsevier B.V. All rights reserved.

Contents

| | |
|---|-----|
| 1. Biology of WNV Infection | 214 |
| 1.1. Ecology, epidemiology, and clinical manifestations | 214 |
| 1.2. Diagnosis | 215 |
| 1.3. Virology and pathogenesis | 215 |
| 1.4. Immune control | 217 |
| 2. Candidate anti-WNV therapeutics | 218 |
| 2.1. Ribavirin and mycophenolic acid | 218 |
| 2.2. Interferon- α | 219 |
| 2.3. Antibodies | 219 |
| 2.4. RNA interference | 220 |
| 2.5. Antisense technology | 220 |
| 2.6. Peptides | 220 |
| 2.7. Imino sugars | 220 |
| 2.8. High-throughput screens with small molecules | 221 |
| 3. Conclusions | 221 |
| References | 221 |

1. Biology of WNV Infection

1.1. Ecology, epidemiology, and clinical manifestations

West Nile virus (WNV) was first isolated in 1937 in the West Nile district of Uganda from a woman with an undiagnosed febrile illness (Smithburn et al., 1940). It is an RNA virus that cycles in nature between *Culex* mosquitoes and birds but also infects and causes disease in humans, horses, and other vertebrate species.

Although its enzootic cycle was believed to be almost exclusively between mosquitoes and birds, with vertebrate species serving as “dead-end” hosts because of low-level and transient viremia, one study demonstrated non-viremic transmission of WNV between co-feeding mosquitoes (Higgs et al., 2005). This suggests that vertebrates may also act as reservoirs for mosquito infection, resulting in further virus transmission.

Historically, WNV caused sporadic outbreaks of a mild febrile illness in regions of Africa, the Middle East, Asia, and Australia. However, in the 1990's, the epidemiology of infection changed. New outbreaks in Eastern Europe were associated with higher rates of severe neurological disease (Hubalek and Halouzka, 1999). In

* Tel.: +1 314 362 2842; fax: +1 314 362 9230.

E-mail address: diamond@borcim.wustl.edu.

1999, WNV entered North America, and caused seven human fatalities in the New York area as well as a large number of avian and equine deaths. Over the last ten years, WNV has spread to all 48 of the lower United States as well as to parts of Canada, Mexico, the Caribbean, and South America. Because of the increased range, the number of human cases has continued to rise: in the United States between 1999 and 2008, 28,961 cases that reached clinical attention were confirmed and associated with 1131 deaths (<http://www.cdc.gov/ncidod/dvbid/westnile/surv&control.htm>).

Most (~85%) of human infections in the United States occur in the late summer with a peak number of cases in August and September. This reflects the seasonal activity of *Culex* mosquito vectors and a requirement for virus amplification in the late spring and early summer in avian hosts. In warmer parts of the country, virtually year-round transmission has been observed. Although more than 100 avian species are susceptible to WNV infection, some are particularly vulnerable with a large number of deaths in crows, blue jays, and hawks. The magnitude of dying birds in a community in the early summer often predicts the severity of human or equine disease weeks later (Komar, 2003). Ecology studies suggest that *Culex pipiens*, the dominant enzootic (bird-to-bird) and bridge (bird-to-human) vector of WNV in urbanized areas in the northeast and north-central United States, shifts its feeding preferences from birds to humans during the late summer and early fall, coincident with the dispersal of its preferred host, the American robin (*Turdus migratorius*) (Kilpatrick et al., 2006).

Seroprevalence studies suggest that most (~80%) cases are sub-clinical, without significant symptoms. Among clinical cases, many develop a self-limiting illness that is termed WNV fever. This syndrome begins after a 2–14-day incubation period and is characterized by fever accompanied with myalgias, arthralgias, headache, fatigue, gastrointestinal complaints, maculopapular rash or lymphadenopathy. This non-neuroinvasive form of WNV infection can be severe as 38% of patients with WNV fever were hospitalized with a mean length stay of 5.4 days (Huhn et al., 2005). A subset of the symptomatic cases progress to the neuroinvasive forms of WNV infection, including acute flaccid paralysis, meningitis, encephalitis, and ocular manifestations (Bakri and Kaiser, 2004; Sejvar et al., 2003); in many instances, a combination of these syndromes is present. Overall, about 1 in 150 WNV infections, result in the most severe and potentially lethal form of the disease. During an epidemic, on a human population scale, the seroconversion rate is ~3% (Mostashari et al., 2001; Tsai et al., 1998) and the attack rate for severe disease during an epidemic is ~7 per 100,000 (Huhn et al., 2005). The risk of severe WNV infection is greatest in the elderly (Chowers et al., 2001; Nash et al., 2001; Tsai et al., 1998). At least two studies have estimated a 20-fold increased risk of neuroinvasive disease and death in those over 50 years of age (Huhn et al., 2005; Nash et al., 2001).

Two human genes, *CCR5* and *OAS1* have been identified as susceptibility loci for WNV infection. In mice, a genetic deficiency of the chemokine receptor *CCR5* was associated with depressed leukocyte trafficking, increased viral burden, and enhanced mortality (Glass et al., 2005). Analogous genetic deficiencies (e.g., *CCR5*Δ32, a deletion in the *CCR5* gene) are associated WNV-induced disease in humans (Glass et al., 2006). Although individuals that are homozygous for the *CCR5*Δ32 allele represent ~1% of the general United States population, 4–8% of individuals with laboratory-confirmed symptomatic WNV infection were homozygous for the mutant allele. Thus, *CCR5* functions as an essential host factor to resist neuroinvasive WNV infection, which may have implications for the use of *CCR5* antagonists (e.g., Maraviroc) in HIV therapy. In certain mouse strains, susceptibility to flaviviruses, including WNV, maps to a truncated isoform of the 2'5' oligoadenylate synthetase (*OAS1b*) gene, a member of an IFN-regulated gene family involved in degradation of viral RNA. A recent study suggests that a hypomorphic allele of

the human ortholog *OAS1* is associated with both symptomatic and asymptomatic WNV infection (Lim et al., 2009). Thus, in humans, variation in *OAS1* is a genetic risk factor for initial WNV infection although not for disease severity.

Although most human WNV infections occur after the bite of an infected *Culex* mosquito, other routes including transfusion, organ transplantation, placental crossing, and through breast milk have resulted in transmission. In 2002, 23 cases of WNV infection were identified after transfusion of blood products (Pealer et al., 2003). These cases led to the development and implementation of nucleic acid amplification tests, which have been used to test pools or individual blood product samples (Busch et al., 2005b; Kleinman et al., 2009; Petersen and Epstein, 2005; Tobler et al., 2005) and largely prevent transmission by transfusion (Busch et al., 2005a). Nucleic acid screening of blood donors have not completely eliminated transfusion-transmitted WNV infections as “breakthrough” infections have occurred, and were attributed to units that had levels of viremia below the sensitivity of the screening assay (Busch et al., 2005b). In addition to transfusion associated WNV infection, several cases by organ transplantation have been reported (DeSalvo et al., 2004; Kleinschmidt-DeMasters et al., 2004; Kumar et al., 2004a,b). In 2007, the FDA approved a screening test for WNV in donated organs (Lang, 2007). Because of the relatively low incidence of WNV infection in organ transplantation and risk of false-positives that can occur with wide scale testing, screening is not mandated (Kiberd and Forward, 2004).

1.2. Diagnosis

Although clinical criteria for assessment of patients with suspected WNV infection have been defined (Granwehr et al., 2004; Sejvar et al., 2003), diagnosis depends on the detection of antibodies or viral nucleic in the blood or cerebrospinal fluid (Zhang et al., 2009). Only a subset of clinical laboratories has the facilities to isolate virus directly from infected clinical samples. Because viremia is relatively transient and often precedes the severe neurological manifestations of the WNV infection, nucleic acid testing although quite specific has a relatively low sensitivity. The detection of WNV IgM in the serum or CSF is still the most utilized method for diagnostic confirmation (Kapoor et al., 2004; Martin et al., 2004). The tests are sensitive (90%) when carried out by day 8 of illness. Nonetheless, testing within the first 72 h of clinical presentation may yield false negative results because of the inherent kinetics of the anti-WNV IgM response (Busch et al., 2008; Diamond et al., 2003b). Because the ELISA test also detects antibodies against related flaviviruses (e.g., St Louis and Japanese encephalitis virus), false positives are possible, and thus it is important to obtain a history of recent vaccination (e.g., yellow fever virus) or foreign travel. Definitive serological diagnosis of WNV infection requires a comparison of antigen or neutralization activity among related flavivirus family members. Investigational diagnostic assays that utilize purified WNV structural and non-structural proteins (Wong et al., 2003, 2004) may allow distinction between natural infection, vaccination, and immunity. One cautionary note is that WNV IgM can persist in serum up to 500 days after onset of infection (Prince et al., 2008, 2007; Roehrig et al., 2003); this could confound interpretation of serology results in patients presenting subsequently with clinical syndromes that resemble WNV infection.

1.3. Virology and pathogenesis

The genus *Flavivirus* is composed of greater than 70 members, 40 of which are associated with human disease: dengue, yellow fever, Japanese encephalitis, tick-borne encephalitis, and West Nile encephalitis viruses are the most important globally, causing extensive morbidity and mortality (Burke and Monath,

2001). Flaviviruses are enveloped RNA viruses with a single-stranded, positive-polarity 11-kilobase genome. They are translated in the cytoplasm as a polyprotein, and then cleaved into structural and non-structural proteins by virus- and host-encoded proteases (Brinton, 2002; Lindenbach and Rice, 2001). The structural proteins include a capsid protein (C), an envelope protein (E) that functions in receptor binding, membrane fusion, and viral assembly, and a transmembrane protein (prM) that assists in proper folding and function of the E protein. The role of the non-structural (NS) proteins is not fully delineated but these proteins form the viral protease (NS2B, NS3), NTPase (NS3), RNA helicase (NS3), RNA-dependent RNA polymerase (NS5), and methyltransferase (NS5) and antagonize host immune responses.

WNV infection occurs following cellular attachment and receptor-mediated endocytosis. Although both DC-SIGN-R and the $\alpha_v\beta_3$ integrin have been suggested as WNV attachment ligands (Chu and Ng, 2004b; Davis et al., 2006), the cellular receptors for WNV on physiologically relevant cell types, such as neurons or macrophages remain uncharacterized. Indeed, more recent studies have reported that WNV entry occurs independently of the $\alpha_v\beta_3$ integrin (Medigeschi et al., 2008). Cellular entry of WNV requires the formation of clathrin-coated pits (Chu and Ng, 2004a; Krishnan et al., 2007) and cholesterol-rich lipid rafts (Medigeschi et al., 2008). Following a pH-dependent conformational change in the E protein (Modis et al., 2004; Zhang et al., 2004), the viral and endosomal membranes fuse, releasing the viral nucleocapsid into the cytoplasm (Allison et al., 1995; Gollins and Porterfield, 1986). Upon nucleocapsid release, viral RNA associates with endoplasmic reticulum (ER) membranes and is translated. Translation is a prerequisite for generating a negative-strand RNA intermediate that serves as a template for nascent positive-strand genomic RNA synthesis (Mackenzie and Westaway, 2001). WNV RNA synthesis is semi-conservative and asymmetric, as positive-strand RNA genome production is about ten times more efficient than negative-strand synthesis (Brinton, 2002). Positive-strand RNA is either packaged within progeny virions or used to translate additional viral proteins. WNV assembles and buds into the ER to form enveloped immature particles containing the prM protein. During egress, immature virions undergo a maturation step in which a furin-like protease cleaves prM (Elshuber et al., 2003; Guirakhoo et al., 1992; Stadler et al., 1997), resulting in a reorganization of E proteins into a distinct homodimeric array (Mukhopadhyay et al., 2003).

Progress has been made on the structural organization WNV, and this has provided insight into the molecular transitions that occur during the virus life cycle (Mukhopadhyay et al., 2005). Three-dimensional reconstruction images from cryoelectron microscopy demonstrate that the WNV has a well-organized outer protein shell, a 40 Å lipid membrane bilayer, and a less-defined inner nucleocapsid core (Mukhopadhyay et al., 2003). The icosahedral scaffold consists of 180 E and M proteins arranged in a repeating herringbone pattern (Kuhn et al., 2002; Zhang et al., 2003a). Structural analysis of the soluble ectodomain of WNV E proteins reveals three domains (Kanai et al., 2006; Nybakken et al., 2006), consistent with earlier studies on related flaviviruses (Modis et al., 2003; Rey, 2003; Rey et al., 1995). Domain I is an 8-stranded β -barrel that participates in the conformational changes associated with the acidification of the endosome (Modis et al., 2004). Domain II, which contains 12 β -strands, has important roles in dimerization, trimerization, and virus-mediated fusion (Modis et al., 2003, 2004; Rey et al., 1995). Domain III adopts an immunoglobulin-like fold, contains the most distal projecting loops on the mature virion (Mukhopadhyay et al., 2003; Zhang et al., 2003a,b), and has been hypothesized to contain the binding site for cell attachment (Beasley and Barrett, 2002; Bhardwaj et al., 2001; Rey et al., 1995; Roehrig et al., 2001). The 180 E monomers lay relatively flat along the virion surface as sets of three anti-parallel homodimers. This mature flavivirus virion has

quasi-icosahedral symmetry, such that three E monomers are found in the asymmetric unit resulting in distinct chemical environments that are available for antibody or receptor binding.

Most strongly neutralizing type-specific antibodies against WNV that have been generated in mice recognize epitopes on Domain III of the E protein (Beasley and Barrett, 2002; Choi et al., 2007; Li et al., 2005; Oliphant et al., 2005; Sanchez et al., 2005; Volk et al., 2004). The crystal structure of a Fab fragment of a neutralizing antibody (E16) in complex with Domain III of WNV E protein provided structural insight into the type-specificity of antibody neutralization (Nybakken et al., 2005). The E16 Fab fragment engaged four discontinuous segments of Domain III including the N-terminal region (residues E302–E309) and three strand-connecting loops: BC (E330–E333), DE (E365–E368) and FG (E389–E391). Comparison of available WNV sequences revealed nearly complete conservation of the structurally defined E16 epitope. Sequence analysis of other flaviviruses revealed diversity in the four segments of the E16 epitope. As individual flavivirus-specific neutralizing antibodies have been mapped to analogous binding regions on Domain III (Gromowski and Barrett, 2007; Hiramatsu et al., 1996; Sukupolvi-Petty et al., 2007; Volk et al., 2004; Wu et al., 2003), this structural epitope, although specific for individual flaviviruses, may have an important role in neutralization of all flaviviruses. More recent studies with human and chimpanzee derived monoclonal antibodies against WNV and related flaviviruses suggest that additional strongly neutralizing antibody epitopes are located within DI, at the DI–DII hinge, and along the DII–dimer interface (Gonzalez et al., 2008; Lai et al., 2007; Vogt et al., 2009).

Infection experiments in animals have contributed to our understanding of the pathogenesis of WNV encephalitis (reviewed in Diamond et al., 2009; Samuel and Diamond, 2006). Based on studies with related flaviviruses, initial replication after mosquito inoculation is believed to occur in the skin in dendritic cells (Ho et al., 2001; Libraty et al., 2001; Marovich et al., 2001; Wu et al., 2000); these infected cells migrate to draining lymph nodes (Johnston et al., 2000) where infection and the risk of dissemination are countered by the development of an early immune response (Bourne et al., 2007; Purtha et al., 2008). After reaching secondary lymphoid tissues, a new round of infection occurs, leading to entry into the circulation via the efferent lymphatic system and thoracic duct. Viremia ensues and after spread to visceral organs (e.g., kidney, and spleen), WNV crosses the blood–brain barrier and enters the central nervous system (Diamond et al., 2003a; Wang et al., 2004; Xiao et al., 2001) through an incompletely understood mechanism. Although WNV likely enters the central nervous system via a hematogenous route (Diamond et al., 2003a; Johnson and Mims, 1968), perhaps as a result of TNF- α or matrix metalloproteinase-9 induced changes in capillary permeability (Wang et al., 2008a, 2004), other mechanisms of entry include retrograde axonal transport through peripheral nerves (Samuel et al., 2007b), transport across the brain microvascular endothelium (Verma et al., 2009), active replication in endothelial cells (Verma et al., 2009), or a “Trojan horse” mechanism in which WNV is carried into the brain by infected inflammatory cells (Burke and Monath, 2001; Dai et al., 2008; Wang et al., 2008b).

In animal models, WNV is first identified in the central nervous system about 3–4 days after infection. Infectious West Nile virus is detected in multiple sites in the brain and spinal cord. Patchy infection of neurons is observed in the cerebral cortex, hippocampus, basal ganglia, cerebellum, brain stem, and anterior horn of the spinal cord (Diamond et al., 2003a; Eldadah and Nathanson, 1967; Eldadah et al., 1967; Xiao et al., 2001). Neuronal infection is associated with degeneration, a loss of cell architecture, and caspase-3 associated apoptosis (Samuel et al., 2007a); this correlates with the development of microglial nodules that surround

infected neurons. Later in the course of infection a mononuclear cell infiltrate appears diffusely throughout infected regions although it is not clear whether these inflammatory cells eradicate infection or contribute to pathogenesis by destroying infected neurons and releasing potentially toxic cytokines (Getts et al., 2008). Of note, Purkinje neurons in the cerebellum (Diamond et al., 2003a; Xiao et al., 2001; Zhang et al., 2008) and motor neurons in the spinal cord are highly vulnerable (Morrey et al., 2008a; Samuel et al., 2007b; Siddharthan et al., 2009). Indeed, the more virulent North American strains of West Nile virus cause a polio-like syndrome in humans that predominantly affects lower motor neuron function (Glass et al., 2002; Leis et al., 2003, 2002). Infection of neurons causes vacuolization, a proliferation of rough endoplasmic reticulum and Golgi-derived membranes, and apoptosis. The expression of WNV proteins may directly induce apoptotic cell death of neurons (Samuel et al., 2007a; Shrestha et al., 2003), possibly due to activation of the unfolded protein response pathway (Medigeschi et al., 2007): accumulation of West Nile virus capsid (Yang et al., 2002, 2008a) and NS3 (Ramanathan et al., 2006) proteins cause apoptosis through activation of caspases 3, 8 and 9.

1.4. Immune control

Although an immunocompromised status predisposes to more severe disease in humans, the individual risk factors, beyond the aforementioned *CCR5* and *OAS1* genes, are not fully characterized. The severity of WNV infection is increased in immunosuppressed patients (Bode et al., 2006; Chan-Tack and Forrest, 2006; Kumar et al., 2004a,b; Murray et al., 2006) suggesting an essential role for immune control mechanisms. The high incidence of WNV neuroinvasive disease in patients on anti-T cell therapies (Kleinschmidt-DeMasters et al., 2004) and in mice with CD4 or CD8 T cell deficiencies (Brien et al., 2007, 2008; Purtha et al., 2007; Shrestha and Diamond, 2004; Sitati and Diamond, 2006; Wang et al., 2003b) indicate that the integrity of adaptive cellular immune responses is essential for clearance of WNV. B cells also protect against disseminated infection as *SCID*, *RAG1* mice and B cell-deficient mice uniformly succumb to WNV infection (Chambers et al., 2008; Diamond et al., 2003a,b; Halevy et al., 1994). Humoral immunity has been linked to peripheral clearance of WNV whereas T cells appear more critical for clearance within the CNS. For example, in CD4 or CD8 T cell-deficient mice, which exhibit increased WNV encephalitis, serum viral loads and IgM levels were no different from wild-type animals but T cell trafficking and/or function in the CNS was impaired (Sitati and Diamond, 2006), indicating that survival is not solely a function of preventing CNS dissemination but also of clearing it.

The past five years has provided new perspective as to how different components of the innate immune response restrict WNV infection. Host cells recognize and respond to RNA virus infection through endosomal the nucleic acid sensors, Toll-like receptor 3 (TLR-3) and 7 (TLR-7), and the cytoplasmic dsRNA sensors, retinoic acid-inducible gene I (RIG-I) and melanoma-differentiation-associated gene 5 (MDA5) (Colonna, 2007; Kawai and Akira, 2006). Binding of RNA to these pathogen recognition receptors (PRRs) results in downstream activation of transcription factors, such as interferon regulatory factors 3 and 7 (IRF-3 and IRF-7), and the expression of IFN and IFN-stimulated genes (ISG). Each of these PRRs demonstrate specificity for different RNA virus families with RIG-I, MDA5, and TLR-3 essential for IFN responses in response to flavivirus infections (Kato et al., 2006). Cultured fibroblasts deficient in RIG-I, MDA5, or IPS-1 demonstrate delayed induction of host responses, decreased IRF-3 activation, and augmented WNV replication (Fredericksen and Gale, 2006; Fredericksen et al., 2008, 2004). In vivo, however, MDA5 may be

less essential for cellular recognition and host response as IFN production by MDA5^{-/-} myeloid dendritic cells remains largely intact after WNV infection (Gitlin et al., 2006). Systemic IFN- α production in mice appears largely independent of the transcription factor, IRF-3 (Bourne et al., 2007; Daffis et al., 2007) but is dependent on IRF-7 (Daffis et al., 2008b). Individual cell types (myeloid, fibroblast, and neuronal) use IRF-3-dependent responses to protect against WNV infection through IFN-dependent and independent pathways (Daffis et al., 2007). In cells that generate robust IFN responses after WNV infection in the absence of IRF-3, alternate sets of PRRs and transcriptional regulators are likely used, including TLR-7/8 and IRF-7.

Recognition of WNV by TLR is mediated by TLR3, which likely binds to viral dsRNA, and TLR7/8, which bind ssRNA, including uridine-rich RNA motifs. Activation of both TLR3 and TLR7/8 in response to viral infection induces production of type I IFN (Alexopoulou et al., 2001; Diebold et al., 2004). However, the signaling pathways that TLR3 and TLR7/8 utilize differ. TLR7/8 recruits the adaptor protein MyD88, which forms a complex with TRAF3, TRAF6, IRAK1 and IRAK4. This complex recruits TAK1, a kinase that activates NF- κ B, or TBK1 and IKK ϵ , kinases that activate IRF-3 and/or IRF-7. TLR3 recruits TRIF, which stimulates the IRF-3/IRF-7-dependent induction of type I IFN genes via interactions with TRAF3, TBK1 and IKK ϵ .

Despite several in vitro studies showing that binding of TLR3 by dsRNA in vitro regulates IFN and other cytokine responses, its role in protection against viral infection in vivo remains less clear. Conflicting results have been observed during WNV infection in mice. Two studies using same TLR3^{-/-} mice reported somewhat opposing phenotypes: Wang and colleagues showed a detrimental role of TLR3 as deficient mice had improved survival rates after WNV infection. This was associated with a mildly increased WNV burden in peripheral tissues yet a decreased proinflammatory cytokine response. The diminished inflammatory response reduced blood–brain barrier permeability and direct entry of WNV into the brain (Wang et al., 2004). A contrasting study showed a protective role with decreased survival of TLR3^{-/-} mice after WNV infection, mildly elevated viral titers in peripheral tissues, and early viral entry in the CNS (Daffis et al., 2008a). At present, it remains unclear why the results are discordant although the disparate route of inoculation and passage history of the virus could impact cytokine responses. TLR3 appears to have an independent role in the CNS, potentially by restricting WNV replication in neurons. TLR3^{-/-} cortical neurons sustained enhanced WNV viral replication, although type I IFN responses were normal. TLR3^{-/-} microglia and astrocytes showed reduced activation and production of proinflammatory cytokines (TNF- α , IL-6 and IL-12 p40) after poly (I:C) challenge (Kim et al., 2008; Town et al., 2006). Thus, the exact contribution of TLR3 for WNV protection requires further study but likely involves direct effects in the CNS.

TLR7 was initially identified as a trigger of the IFN- α response after exposure to ssRNA from influenza or other viruses (Hornung et al., 2008). TLR7 was also characterized as the primary PRR responsible for systemic IFN production by plasmacytoid DC through a MyD88-dependent pathway (Asselin-Paturel and Trinchieri, 2005). The contribution of TLR7 in protecting from WNV infection in vivo was recently examined (Town et al., 2009). TLR7^{-/-} mice were more vulnerable to WNV infection and sustained increased viremia after infection. These mice showed a defect of immune cell homing to WNV-infected tissues via a novel IL-23-dependent mechanism. Interestingly, systemic levels of proinflammatory cytokines (IL-6, TNF- α , and IL-12) and type I IFN were higher in TLR7^{-/-} mice when compared to wild-type animals. This result suggests that abrogation of the TLR7 pathway has little systemic impact on IFN production after WNV infection.

The complement system is a family of serum proteins and cell surface molecules that participate in pathogen recognition and clearance. Complement contributes to host protection through direct opsonization and/or cytolysis, chemotaxis, immune clearance, and modulation of B and T cell functions (Carroll, 2004). Complement is required for protection from lethal WNV infection in mice. WNV activates complement *in vivo*, and mice lacking in the central complement component C3 or complement receptors (CR)1 and 2 showed enhanced lethality after WNV infection (Mehlhop and Diamond, 2006; Mehlhop et al., 2005). All three complement activation pathways coordinate control against WNV, as mice deficient in molecules of the alternative, classical, or lectin pathway exhibit increased mortality. Interestingly, the activation pathways modulated WNV infection through distinct mechanisms. Alternative pathway-deficient mice demonstrated normal B cell function but impaired CD8⁺ T cell responses, whereas classical and lectin pathway-deficient mice had defects both in WNV-specific antibody production and T cell responsiveness (Mehlhop and Diamond, 2006).

Complement also augments the efficacy of IgG antibodies against WNV. Whereas initial studies with anti-WNV IgM antibodies suggested that complement could efficiently enhance WNV infection in macrophages *in vitro* (Cardosa et al., 1986, 1983), more recent investigations indicate that the complement component C1q augments the potency of neutralizing antibody against WNV in an IgG subclass-specific manner (E. Mehlhop, S. Nelson, T. Pierson, and M. Diamond, manuscript submitted), analogous to that observed for other viruses including measles (Iankov et al., 2006), influenza (Feng et al., 2002; Mozdzanowska et al., 2006), vesicular stomatitis (Beebe and Cooper, 1981), and human immunodeficiency (Aasa-Chapman et al., 2005; Spruth et al., 1999) viruses. C1q also restricts antibody-dependent enhancement of WNV infection *in vitro* and *in vivo* (Mehlhop et al., 2007).

While few studies have directly addressed the function of cellular innate immunity in WNV infection, macrophages and dendritic cells likely inhibit WNV through direct viral clearance, enhanced antigen presentation, and cytokine and chemokine secretion. Consistent with this, depletion of myeloid cells systemically or in the draining lymph nodes enhanced lethality in mice after WNV infection (Ben-Nathan et al., 1996; Purtha et al., 2008). Macrophages basally express key host defense molecules, including RIG-I, MDA5, ISG54, and ISG56, and thus, restrict WNV infection by inducing type I IFN (Daffis et al., 2007) and other inhibitory cytokines. Macrophages may also control flaviviruses through the production of nitric oxide (NO) intermediates (Kreil and Eibl, 1996; Lin et al., 1997), although the role of NO in WNV infection has not been established.

$\gamma\delta$ T cells also function in early immune responses and directly limit WNV infection. As they lack MHC restriction, $\gamma\delta$ T cells can react with viral antigens in the absence of conventional antigen processing (Steele et al., 2000). $\gamma\delta$ T cells expand following WNV infection (Welte et al., 2008), and increased viral burden and mortality and delayed priming of adaptive immune responses were observed in mice deficient in $\gamma\delta$ T cells (Wang et al., 2006, 2003a). Bone marrow chimera reconstitution experiments demonstrated that $\gamma\delta$ T cells require IFN- γ to limit WNV infection (Shrestha et al., 2006b). Natural killer (NK) cells also have the potential to control WNV infection through recognition and elimination of virus-infected cells. NK cell activity was transiently activated and then suppressed following flavivirus infection in mice (Shrestha et al., 2004; Vargin and Semenov, 1986). As WNV infection increases surface expression of class I MHC molecules by enhancing the transport activity of TAP and by NF- κ B-dependent transcriptional activation of MHC class I genes (Douglas et al., 1994; King and Kesson, 1988; Liu et al., 1988), natural killing may be inhibited (Diamond, 2003; King and Kesson, 2003; King et al., 1989). Notably,

antibody depletion of NK cells in mice did not alter morbidity or mortality after WNV infection (Chung et al., 2007; Shrestha et al., 2006a).

2. Candidate anti-WNV therapeutics

At present, no specific therapy has been approved for use in humans with WNV infection as current treatment is supportive. Tissue culture and animal model studies have applied multiple strategies for the generation of novel therapies against WNV, and possibly other flaviviruses. Nonetheless, the development of therapeutics that mitigate or abort disease is challenging as patients with the most severe disease often have underlying immune deficits and present to clinical attention relatively late in their course (Granwehr et al., 2004; Jackson, 2004). Among the additional impediments will be developing therapeutics that efficiently cross into the central nervous system and clear virus from infected neurons. Finally, once a candidate agent is identified, regulatory hurdles will be encountered in the design and implementation of multi-center trials given the sporadic temporal and spatial occurrence of WNV infections (Jester et al., 2006).

2.1. Ribavirin and mycophenolic acid

Ribavirin is a broad-spectrum antiviral agent and has been used clinically to treat respiratory syncytial (Hall et al., 1983), hepatitis C (Davis et al., 1998), Lassa (McCormick et al., 1986), Hantaan (Huggins et al., 1991) and La Crosse (McJunkin et al., 1997) viruses. It acts as a guanosine analogue and competitively inhibits inosine monophosphate dehydrogenase (IMP), resulting in depleted intracellular guanosine pools (Leyssen et al., 2005). This may interfere with the guanylation step of RNA capping, inhibit viral polymerases or compromise the integrity of the viral genome by being incorporated directly into the nascent RNA strand and serving as a template for both cytidine and uridine (Crotty et al., 2000; Day et al., 2005). Ribavirin has inhibitory activity against WNV infection in cell culture (Anderson and Rahal, 2002; Day et al., 2005; Jordan et al., 2000) at high doses (EC₅₀ of 60–100 μ M). Limited animal studies have been performed with less than promising results. Treatment of WNV-infected hamsters with ribavirin increased mortality (Morrey et al., 2004). Moreover, during a WNV outbreak in Israel in 2000, 37 patients received ribavirin and a high mortality rate (41%) was observed in this group (Chowers et al., 2001).

Mycophenolic acid (MPA) is a non-nucleoside inhibitor of IMP dehydrogenase that is used clinically to prevent rejection of transplanted organs. The immunosuppressive properties of MPA are attributed to its anti-proliferative effect on lymphocytes *in vitro* (Allison and Eugui, 1993; Nagy et al., 1993). MPA inhibits to varying degrees the replication of a number of DNA, RNA, and retroviruses *in vitro* including arenaviruses, Sindbis virus, reovirus, parainfluenza virus, coxsackie virus, Epstein-Barr virus, hepatitis B virus, and HIV (Gong et al., 1999; Ichimura and Levy, 1995; Neyts and De Clercq, 1998). Four studies have demonstrated that MPA inhibits flavivirus infection including WNV in cells by limiting viral RNA replication (Diamond et al., 2002; Morrey et al., 2002; Ng et al., 2007; Takhampunya et al., 2006). Although MPA blocked WNV infection efficiently in cell culture, *in vivo* its inhibitory properties were overshadowed by its immunosuppressive effects. Increased mortality after WNV infection was observed in mice treated with several different doses of MPA (B. Geiss and M. Diamond, unpublished results). Thus, the pre-clinical data suggests that inhibitors of guanosine biosynthesis are not therapeutic candidates against WNV infection, likely because of their effects on immune system function.

2.2. Interferon- α

Type I IFNs (IFN- α and β) comprise an important innate immune system control against viral infections. IFNs induce an antiviral state within cells through the induction of antiviral proteins and by modulating adaptive immune responses (Samuel, 1991). Pretreatment of cells *in vitro* with type I IFN potently inhibits flaviviruses including WNV (Anderson and Rahal, 2002; Best et al., 2005; Crance et al., 2003; Diamond and Harris, 2001; Diamond et al., 2000; Fredericksen et al., 2004; Samuel et al., 2006). However, the inhibitory effect of IFN is markedly attenuated after viral replication has begun (Diamond et al., 2000; Lin et al., 2004) as flavivirus non-structural proteins antagonize type I IFN effects by preventing JAK1 and Tyk2 phosphorylation, STAT1 and STAT2 signaling, and IFN- β gene transcription (Ashour et al., 2009; Best et al., 2005; Evans and Seeger, 2007; Jones et al., 2005; Lin et al., 2008, 2004; Liu et al., 2004, 2006, 2005; Munoz-Jordan et al., 2005, 2003). Nonetheless, IFN may still have therapeutic potential. Mice that were deficient in IFN- α and β receptors were acutely vulnerable to WNV infection with 100% mortality and a mean time to death of ~4 days after subcutaneous inoculation with 1 PFU of virus (Samuel and Diamond, 2005). Pretreatment of rodents with IFN- α inhibited St. Louis encephalitis virus infection and resulted in decreased WNV viral loads and mortality (Brooks and Philippotts, 1999; Morrey et al., 2004). Treatment with IFN- α reduced complications in human St. Louis encephalitis virus cases and has been used in an uncontrolled manner to treat small numbers of human cases of WNV encephalitis (Kalil et al., 2005; Lewis and Amsden, 2007; Rahal et al., 2004; Sayao et al., 2004). Nonetheless, in Vietnam, a double-blinded, randomized placebo controlled clinical trial was performed on 1112 children with suspected or documented Japanese encephalitis virus infection; treatment with IFN α_{2a} failed to improve outcome (Solomon et al., 2003).

2.3. Antibodies

Although antibody has been utilized as a therapeutic against several viral infections (Sawyer, 2000; Zeitlin et al., 1999), with the exception of its prophylactic use against tick-borne encephalitis virus, it has not been used extensively against flavivirus infections in humans. Most neutralizing antibodies recognize the structural E protein, although a subset also have been described against another virion-associated protein, the prM or membrane protein (Colombage et al., 1998; Falconar, 1999; Pincus et al., 1992; Vazquez et al., 2002). Several groups also have generated non-neutralizing, yet protective mAbs against NS1 (Chung et al., 2006, 2007; Despres et al., 1991; Falgout et al., 1990; Henchal et al., 1988; Putnak and Schlesinger, 1990; Schlesinger et al., 1986, 1990, 1987; Schlesinger and Chapman, 1995), a protein that is absent from the virion. Thus, protection against flavivirus infections *in vivo* does not always correlate with neutralizing activity *in vitro* (Brandriss et al., 1986; Roehrig et al., 1983; Schlesinger et al., 1985). The ability to cure rodents of flavivirus infection with immune serum or monoclonal antibodies depends on the dosage and time of administration (Camenga et al., 1974; Chiba et al., 1999; Kimura-Kuroda and Yasui, 1988; Oliphant et al., 2005; Philippotts et al., 1987; Roehrig et al., 2001), and polyclonal antibodies that prevent infection against one flavivirus do not provide durable cross-protection against heterologous flaviviruses (Broom et al., 2000; Roehrig et al., 2001).

Although these studies suggest that antibodies could have a potential therapeutic role, there are at least theoretical concerns that treatment could exacerbate disease. Sub-neutralizing concentrations of antibody enhance flavivirus replication in myeloid cells *in vitro* (Cardosa et al., 1986, 1983; Gollins and Porterfield, 1984, 1985; Peiris and Porterfield, 1979; Peiris et al., 1981, 1982; Pierson et al., 2007) and *in vivo* (Gonzalez et al., 2007; Mehlhop et al.,

2007), and thus could complicate the antibody therapy. This phenomenon of antibody-dependent enhancement of infection (ADE) may cause the pathologic cytokine cascade that occurs during secondary dengue virus infection (Halstead, 1989; Halstead et al., 1980; Kurane and Ennis, 1992; Morens, 1994); despite its extensive characterization *in vitro*, the significance of ADE *in vivo* with WNV or other flaviviruses remains uncertain. Apart from or perhaps related to ADE, an “early-death” phenomenon (Morens, 1994) has been reported that could also limit the utility of antibody therapy. According to this model, animals that have pre-existing humoral immunity but do not respond well to viral challenge may succumb to infection more rapidly than animals without pre-existing immunity. Although it has been described after passive acquisition of antibodies against yellow fever and Langkat encephalitis viruses (Barrett and Gould, 1986; Gould et al., 1987; Gould and Buckley, 1989; Webb et al., 1968), this phenomenon was not observed after transfer of monoclonal or polyclonal antibodies against Japanese (Kimura-Kuroda and Yasui, 1988) or tick-borne (Kreil and Eibl, 1997) encephalitis viruses.

Passive administration of anti-WNV antibodies is both protective and therapeutic and does not cause adverse effects related to immune enhancement. Transfer of immune serum prior to WNV infection protected wild-type, B cell-deficient (μ MT), and T and B cell-deficient (*RAG1*) mice from infection (Diamond et al., 2003a) and no increased mortality was observed even when sub-neutralizing concentrations of antibodies were used. Similarly, passive administration of immune serum (Tesh et al., 2002) or antiserum that recognized WNV E protein (Wang et al., 2001) protected hamsters and mice against lethal WNV infection. In therapeutic trials, immune human γ -globulin protected mice against WNV-induced mortality (Ben-Nathan et al., 2009, 2003; Engle and Diamond, 2003; Julander et al., 2005). Therapeutic intervention even 5 days after infection reduced mortality; this time point is significant because WNV spreads to the brain and spinal by day 4. Thus, passive transfer of immune antibody improved clinical outcome even after WNV had disseminated into the CNS.

Small numbers of human patients have received immunotherapy against WNV infection. Prophylaxis and therapy with neutralizing anti-WNV antibodies may be a possible intervention in the elderly and immunocompromised. Case reports (Haley et al., 2003; Hamdan et al., 2002; Saquib et al., 2008; Shimoni et al., 2001) have documented improvement in humans with neuroinvasive WNV infection after receiving immune γ -globulin from Israeli donors. Given the endemic nature of WNV in the Middle East, pooled human immunoglobulin from Israeli donors was shown to contain significant neutralizing titers of antibodies against WNV (Ben-Nathan et al., 2009, 2003; Engle and Diamond, 2003). Although promising, γ -globulin immunotherapy against WNV infection in humans has limitations: (a) batch variability may affect the quantitative titer, functional activity, and therapeutic efficacy of specific antibody preparations; (b) it is purified from human blood plasma, and has an inherent risk of transmitting known and unknown infectious agents; and (c) it requires a large volume of administration, which can increase adverse events in patients with cardiac or renal co-morbidities.

To overcome these limitations, humanized or human monoclonal antibodies or antibody fragments with therapeutic activity against WNV infection (Gould et al., 2005; Oliphant et al., 2005; Throsby et al., 2006; Vogt et al., 2009) have been developed by several groups. These human or humanized antibody fragments have high neutralizing activity *in vitro* and provide excellent protection *in vivo* in mice. If mAbs are to be an effective therapy for WNV encephalitis they should function after the onset of symptoms and ideally, after infection in the central nervous system. When mouse or humanized mAbs were given as a single dose 5 or 6 days after infection 90% of mice or hamsters were pro-

tected (Morrey et al., 2006, 2007; Oliphant et al., 2005). Acute flaccid paralysis in hamsters also was blocked by treatment with one neutralizing mAb, E16 several days after infection (Samuel et al., 2007b). MacroGenics has initiated a phase I/II randomized, double-blinded clinical trial to evaluate safety and efficacy of the E16 antibody (also termed MGAWN1) against severe WNV infection (<http://clinicaltrials.gov/ct2/show/NCT00515385>). Thus, neutralizing antibody therapeutics show promise as they directly inhibit transneuronal spread of WNV infection and prevent the development of paralysis in vivo. Future use of a combination of monoclonal antibodies that bind distinct epitopes and neutralize by independent mechanisms could diminish the potential risk of selecting escape variants in vivo (Zhang et al., *in press*), especially in immunocompromised individuals who generate high-grade viremia and tissue viral burden.

2.4. RNA interference

RNA interference (RNAi) is a cellular process that specifically degrades RNA within the cytoplasm of cells in a sequence-specific manner (Meister et al., 2004). RNAi occurs in plants, nematodes, parasites, insects, and mammalian cells and is believed to function as a regulator of cellular gene expression and possibly as an innate defense against RNA viruses (Voinnet, 2005; Waterhouse et al., 2001). RNAi uses double-stranded RNA (dsRNA) to target and degrade sequence-specific single-stranded RNA. The cytoplasmic ribonuclease DICER recognizes and cleaves long dsRNA molecules into 21–30 base pair small interfering RNA (siRNA) molecules; these associate with the RNA Induced Silencing Complex (RISC) to target and degrade complementary single-stranded RNA molecules (Sontheimer, 2005).

RNAi is now widely used to transiently disrupt various gene products to study their function in cells. Many mammalian viruses appear susceptible to treatment with exogenous siRNA. Cells that express virus-specific siRNA are resistant to infection by WNV (Anthony et al., 2009; Bai et al., 2005; Geiss et al., 2005; McCown et al., 2003; Ong et al., 2008; Yang et al., 2008b) in vitro. The sequence specific activity of siRNA against viruses has led to great interest in its potential as a new class of antiviral therapy. Two studies have shown that administration of siRNA to mice reduces WNV load and affords partial protection against lethal challenge (Bai et al., 2005; Kumar et al., 2006). Studies were also performed to determine whether WNV-specific siRNA could act efficiently as a therapeutic by administering it after viral challenge. Although siRNA could protect against lethal infection when given within 6 h of infection (Kumar et al., 2006), no significant difference in survival was observed when siRNA was delivered 24 h after infection (Bai et al., 2005). In vitro studies may explain some of the attenuated therapeutic effect of siRNA as pre-treatment but not post-treatment of cells with siRNA greatly reduced WNV replication and infection (Geiss et al., 2005). Because flaviviruses replicate in a specialized membranous compartment (Welsch et al., 2009), its genome may not be exposed to the cytoplasmic RNAi machinery. RNAi based therapeutics against WNV may await the development of enhanced delivery systems that allow siRNA to efficiently cross intracellular membranes and inhibit actively replicating viruses.

2.5. Antisense technology

Antisense oligomers have been used to modulate gene expression of pathogenic viruses, and several are in clinical development or trials (Kinney et al., 2005; Ma et al., 2000). This class of compounds inhibits viruses by binding to RNA in a sequence-specific manner, effectively blocking access to a particular region of the viral genome. The development of phosphorodiamidate morpholino oligomers (PMO) has overcome prior limitations by

enhancing water solubility and nuclease resistance (Summerton et al., 1997). The conjugation of arginine-rich peptides to PMOs has facilitated cellular uptake and inhibitory activity in cell culture systems (Neuman et al., 2004). Sequence-specific antisense oligomers have inhibitory activity against several flaviviruses, including WNV in cell culture (Deas et al., 2005; Kinney et al., 2005; Raviprakash et al., 1995; Stein and Shi, 2008). Low micromolar (5–20 μ M) concentrations of arginine-rich peptide-conjugated PMOs that targeted the 5' untranslated or 3' cyclization sequences inhibited WNV by 5–6 log₁₀ PFU/ml (Deas et al., 2005; Kinney et al., 2005). However, effective suppression of viral replication in vitro required PMO to be present before or soon after infection, as administration at either 2 or 4 days after infection had little or no antiviral effect. PMO directed against the 5' and 3' conserved sequences partially protected mice from WNV disease without causing appreciable toxicity, although selection of resistant mutants was observed (Deas et al., 2007). Some clinical improvement was observed even when PPO was administered to mice at day 5 after infection although statistically significant differences were not achieved. AVI Biopharma has initiated a phase I/II human clinical study for treatment of WNV infection (<http://www.clinicaltrials.gov/ct/show/NCT00091845>) with AVI-4020. This trial is a randomized, double-blinded study that is focused on determining safety, tolerability, pharmacokinetics, and potential efficacy.

2.6. Peptides

The hemagglutinin of influenza virus is a prototypical class I viral envelope fusion protein. In response to receptor engagement and acid pH, the α helices of the viral hemagglutinin rearrange and expose an N-terminal fusion peptide that facilitates fusion of two lipid membranes and viral entry (Carr and Kim, 1993). Importantly, peptide mimics of the class I fusion proteins of HIV (Sodroski, 1999), Sendai (Rapaport et al., 1995), Newcastle (Young et al., 1999), and herpes (Okazaki and Kida, 2004) viruses efficiently inhibit entry and infection. Indeed, Fuzeon™ is a fusion inhibitor approved for clinical use in HIV-infected patients. The flavivirus E proteins are structurally distinct from the class I fusion proteins, and together with the envelope proteins of alphaviruses comprise a second class of viral fusion proteins. Class II fusion proteins facilitate viral entry and nucleocapsid release after undergoing an analogous series of pH-dependent conformational changes (Bressanelli et al., 2004; Kuhn et al., 2002; Lescar et al., 2001; Modis et al., 2004). Using an algorithm that predicted peptide inhibitors of class I fusion proteins, one group identified inhibitory peptides in WNV and dengue virus E protein that correspond to the proposed fusion and stem anchor domains. Low micromolar concentrations of these peptides inhibited WNV and dengue virus infection in cell culture in a sequence-specific manner (Hrobowski et al., 2005). As an alternative approach, another group identified two E protein peptides that could inhibit WNV infection with EC₅₀ values as low as ~3 μ M. Mice challenged with WNV that had been administered these inhibitory peptides showed reduced viremia and lethality (Bai et al., 2006).

2.7. Imino sugars

Flavivirus assembly takes place within the endoplasmic reticulum (ER). The structural glycoproteins prM and E localize to the luminal side of the ER and encapsidate as an immature particle with prM and E in a heterodimeric complex (Chambers et al., 1990; Zhang et al., 2003b). In flavivirus-infected mammalian cells, a 14-residue oligosaccharide (Glc)₃(Man)₉(GlcNAc)₂ is added in the ER to specific asparagine residues specific on the prM and E proteins. This high mannose carbohydrate is sequentially modified in the ER and Golgi by resident glucosidases to generate N-linked glycans that

lack the terminal $\alpha(1,2)$ and $\alpha(1,3)$ glucose residues (Hebell et al., 1991). Trimming of N-linked carbohydrates in the ER is required for proper assembly or secretion of flaviviruses (Courageot et al., 2000; Wu et al., 2002). Imino sugar derivatives, such as deoxynorjirimycin or castanospermine, inhibit endoplasmic reticulum α -glucosidases I and II. This prevents processing of high mannose N-linked glycans from nascent glycoproteins, a step that is required for interaction with the ER chaperones, calnexin and calreticulin. Several flaviviruses are strongly inhibited by α -glucosidase inhibitors in vitro and in vivo (Chang et al., 2009; Courageot et al., 2000; Gu et al., 2007; Schul et al., 2007; Whitby et al., 2005; Wu et al., 2002). More recently, a family of imino sugar derivatives was synthesized with superior antiviral activity (EC_{50} of ~ 0.1 – 1 mM) and low toxicity (selectivity index ~ 100) against several flaviviruses, including WNV (Chang et al., 2009). One possible advantage of α -glucosidase inhibitors is that they target a host enzyme that is an essential step in virus secretion rather than the virus directly, and are thus, less likely to select for resistant variants.

2.8. High-throughput screens with small molecules

Over the last five years, high-throughput screens with small molecule libraries have been performed by several groups and identified classes of “druggable” compounds that inhibit WNV. Inhibitors have been identified that attenuate WNV translation, protease activity, and replication (Borowski et al., 2002; Goodell et al., 2006; Gu et al., 2006; Johnston et al., 2007; Nouiery et al., 2007; Puig-Basagoiti et al., 2006). Gu et al. (2006) used a cell-based WNV subgenomic replicon to screen 35,000 compounds and identify pyrozolopyrimidine compounds with anti-WNV activity. Puig-Basagoiti et al. (2006) used a full length WNV that expressed a luciferase reporter gene to identify a triaryl pyrazoline compound that inhibits flavivirus RNA replication with an EC_{50} of ~ 15 μ M. Nouiery et al. (Nouiery et al., 2007) evaluated a chemical library of 80,000 compounds for their ability to inhibit reporter gene expression from a WNV replicon; they identified inhibitory secondary sulfonamides and cyclopenta pyridines with EC_{50} values of ~ 3 μ M. Johnston et al. (2007) screened a 65,000 compound library for the ability to inhibit NS2B-NS3 protease; they identified a common 5-amino-1H-pyrazol-3-yl scaffold as non-competitive inhibitors of WNV protease activity. Analogously, Mueller et al. (2008) utilized a high-throughput assay to screen 32,000 compounds for inhibition of the WNV protease; lead compounds in the 8-hydroxyquinolone family bound in the substrate cleft and inhibited the protease.

Fewer studies have been performed with small molecules in animals to assess their therapeutic potential. One oral pyrazine derivative with broad-spectrum antiviral activity, T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) was protective in rodents when administered twice daily beginning 2 days after WNV infection (Morrey et al., 2008b). However, administration of T-705 at days 3 or 4 after infection showed little apparent efficacy. Another preliminary study showed that oral active hexose could protect against lethal WNV infection in young and old mice by augmenting early antibody and $\gamma\delta$ T cell responses (Wang et al., 2009). Although no post-exposure therapeutic trials were performed, they raise the possibility that dietary supplementation with oral active forms of hexose could improve antiviral immune responses and decrease the risk of severe neuroinvasive WNV disease.

3. Conclusions

Given the lack of existing therapies and its continued global emergence, the development of antiviral agents against WNV is essential. At present, several candidate therapies that act through distinct mechanisms are moving through various stages of pre-

clinical development. Based on the epidemiology and pathogenesis of severe WNV infection effective antiviral agents against WNV must have minimal detrimental effects on immune system function. Even with the identification of new classes of anti-WNV agents, a major hurdle remains as to whether they can be administered in a timely manner before extensive and irreversible neuronal injury occurs. Technical challenges will include creating inhibitors that efficiently cross the blood–brain barrier to allow for control of WNV replication within neurons. Regulatory hurdles will be encountered in implementing multi-center trials. It may be difficult to define referral sites that can recruit adequate numbers of patients so that statistically meaningful data can be acquired and analyzed. Unlike other diseases with high incidence, it may take years to complete a WNV clinical trial. With the introduction of several classes of candidate antiviral agents, there may be competition for patient cohorts. Because of this, extensive pre-clinical experiments in small animals, horses, and non-human primates may be useful to define whether a candidate therapeutic against WNV reaches human clinical trials.

Ongoing pathogenesis and infection studies undoubtedly will inform novel drug design strategies that target individual viral proteins (Dong et al., 2008). Experiments in animals should continue to define the essential components of the protective immune response, and the immunologic risk factors that predispose to severe neurological disease. Ultimately, a combination drug strategy that blocks viral replication, boosts protective immune responses, minimizes neuronal injury, and limits the development of resistant variants will likely be more effective than single agents.

References

- Aasa-Chapman, M.M., Holuigue, S., Aubin, K., Wong, M., Jones, N.A., Cornforth, D., Pellegrino, P., Newton, P., Williams, I., Borrow, P., McKnight, A., 2005. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. *J. Virol.* 79, 2823–2830.
- Alexopoulou, L., Holt, A.C., Medzhitov, R., Flavell, R.A., 2001. Recognition of double-stranded RNA and activation of NF- κ B by Toll-like receptor 3. *Nature* 413, 732–738.
- Allison, A.C., Eugui, E.M., 1993. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. *Immunol. Rev.* 136, 5–28.
- Allison, S.L., Schlich, J., Stiasny, K., Mandl, C.W., Kunz, C., Heinz, F.X., 1995. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. *J. Virol.* 69, 695–700.
- Anderson, J.F., Rahal, J.J., 2002. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. *Emerg. Infect. Dis.* 8, 107–108.
- Anthony, K.G., Bai, F., Krishnan, M.N., Fikrig, E., Koski, R.A., 2009. Effective siRNA targeting of the 3′ untranslated region of the West Nile virus genome. *Antiviral Res.* 82, 166–168.
- Ashour, J., Laurent-Rolle, M., Shi, P.Y., Garcia-Sastre, A., 2009. NS5 of dengue virus mediates STAT2 binding and degradation. *J. Virol.* 83, 5408–5418.
- Asselin-Paturel, C., Trinchieri, G., 2005. Production of type I interferons: plasmacytoid dendritic cells and beyond. *J. Exp. Med.* 202, 461–465.
- Bai, F., Town, T., Pradhan, D., Cox, J., Ashish, Ledizet, M., Anderson, J.F., Flavell, R.A., Krueger, J.K., Koski, R.A., Fikrig, E., 2006. Antiviral peptides targeting the West Nile Virus envelope protein. *J. Virol.* 81, 2047–2055.
- Bai, F., Wang, T., Pal, U., Bao, F., Gould, L.H., Fikrig, E., 2005. Use of RNA interference to prevent lethal murine West Nile virus infection. *J. Infect. Dis.* 191, 1148–1154.
- Bakri, S.J., Kaiser, P.K., 2004. Ocular manifestations of West Nile virus. *Curr. Opin. Ophthalmol.* 15, 537–540.
- Barrett, A.D., Gould, E.A., 1986. Antibody-mediated early death in vivo after infection with yellow fever virus. *J. Gen. Virol.* 67, 2539–2542.
- Beasley, D.W., Barrett, A.D., 2002. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. *J. Virol.* 76, 13097–13100.
- Beebe, D.P., Cooper, N.R., 1981. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. *J. Immunol.* 126, 1562–1568.
- Ben-Nathan, D., Gershoni-Yahalom, O., Samina, I., Khinich, Y., Nur, I., Laub, O., Gotreich, A., Simanov, M., Porgador, A., Rager-Zisman, B., Orr, N., 2009. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. *BMC Infect. Dis.* 9, 18.
- Ben-Nathan, D., Huitinga, I., Lustig, S., van Rooijen, N., Kobiler, D., 1996. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. *Arch. Virol.* 141, 459–469.
- Ben-Nathan, D., Lustig, S., Tam, G., Robinson, S., Segal, S., Rager-Zisman, B., 2003. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating west Nile virus infection in mice. *J. Infect. Dis.* 188, 5–12.

- Best, S.M., Morris, K.L., Shannon, J.G., Robertson, S.J., Mitzel, D.N., Park, G.S., Boer, E., Wolfenbarger, J.B., Bloom, M.E., 2005. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. *J. Virol.* 79, 12828–12839.
- Bhardwaj, S., Holbrook, M., Shope, R.E., Barrett, A.D., Watowich, S.J., 2001. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. *J. Virol.* 75, 4002–4007.
- Bode, A.V., Sejvar, J.J., Pape, W.J., Campbell, G.L., Marfin, A.A., 2006. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. *Clin. Infect. Dis.* 42, 1234–1240.
- Borowski, P., Lang, M., Haag, A., Schmitz, H., Choe, J., Chen, H.M., Hosmane, R.S., 2002. Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme. *Antimicrob. Agents Chemother.* 46, 1231–1239.
- Bourne, N., Scholle, F., Silva, M.C., Rossi, S.L., Dewsbury, N., Judy, B., De Aguiar, J.B., Leon, M.A., Estes, D.M., Fayzulin, R., Mason, P.W., 2007. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. *J. Virol.* 81, 9100–9108.
- Brandriss, M.W., Schlesinger, J.J., Walsh, E.E., Briselli, M., 1986. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. *J. Gen. Virol.* 67, 229–234.
- Bressanelli, S., Stiasny, K., Allison, S.L., Stura, E.A., Duquerroy, S., Lescar, J., Heinz, F.X., Rey, F.A., 2004. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. *Embo J.* 23, 728–738.
- Brien, J.D., Uhrhlaub, J.L., Nikolich-Zugich, J., 2007. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. *Eur. J. Immunol.* 37, 1855–1863.
- Brien, J.D., Uhrhlaub, J.L., Nikolich-Zugich, J., 2008. West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. *J. Immunol.* 181, 8568–8575.
- Brinton, M.A., 2002. The molecular biology of West Nile Virus: a new invader of the western hemisphere. *Annu. Rev. Microbiol.* 56, 371–402.
- Brooks, T.J., Phillips, R.J., 1999. Interferon- α protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. *Antiviral Res.* 41, 57–64.
- Broom, A.K., Wallace, M.J., Mackenzie, J.S., Smith, D.W., Hall, R.A., 2000. Immunisation with gamma globulin to Murray Valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against Australian encephalitis: evaluation in a mouse model. *J. Med. Virol.* 61, 259–265.
- Burke, D.S., Monath, T.P., 2001. Flaviviruses. In: Knipe, D.M., Howley, P.M. (Eds.), *Fields Virology*, vol. 1. Lippincott Williams & Wilkins, Philadelphia, pp. 1043–1125.
- Busch, M.P., Caglioti, S., Robertson, E.F., McAuley, J.D., Tobler, L.H., Kamel, H., Linnen, J.M., Shyamala, V., Tomasulo, P., Kleinman, S.H., 2005a. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. *N. Engl. J. Med.* 353, 460–467.
- Busch, M.P., Kleinman, S.H., Tobler, L.H., Kamel, H.T., Norris, P.J., Walsh, J.L., Prince, H.E., Lanciotti, R.S., Wright, D.J., Linnen, J.M., Caglioti, S., 2008. Virus and antibody dynamics in acute west nile virus infection. *J. Infect. Dis.* 198, 984–993.
- Busch, M.P., Tobler, L.H., Saldanha, J., Caglioti, S., Shyamala, V., Linnen, J.M., Gallarda, J., Phelps, B., Smith, R.L., Drebot, M., Kleinman, S.H., 2005b. Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003. *Transfusion* 45, 492–499.
- Camenga, D.L., Nathanson, N., Cole, G.A., 1974. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. *J. Infect. Dis.* 130, 634–641.
- Cardosa, M.J., Gordon, S., Hirsch, S., Springer, T.A., Porterfield, J.S., 1986. Interaction of West Nile virus with primary murine macrophages: role of cell activation and receptors for antibody and complement. *J. Virol.* 57, 952–959.
- Cardosa, M.J., Porterfield, J.S., Gordon, S., 1983. Complement receptor mediates enhanced flavivirus replication in macrophages. *J. Exp. Med.* 158, 258–263.
- Carr, C.M., Kim, P.S., 1993. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. *Cell* 73, 823–832.
- Carroll, M.C., 2004. The complement system in regulation of adaptive immunity. *Nat. Immunol.* 5, 981–986.
- Chambers, T.J., Droll, D.A., Walton, A.H., Schwartz, J., Wold, W.S., Nickells, J., 2008. West Nile 25A virus infection of B-cell-deficient ((micro)MT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral envelope protein. *J. Gen. Virol.* 89, 627–635.
- Chambers, T.J., Hahn, C.S., Galler, R., Rice, C.M., 1990. Flavivirus genome organization, expression, and replication. *Annu. Rev. Microbiol.* 44, 649–688.
- Chan-Tack, K.M., Forrest, G., 2006. West Nile virus meningoencephalitis and acute flaccid paralysis after infliximab treatment. *J. Rheumatol.* 33, 191–192.
- Chang, J., Wang, L., Ma, D., Qu, X., Guo, H., Xu, X., Mason, P.M., Bourne, N., Moriarty, R., Gu, B., Guo, J.T., Block, T.M., 2009. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. *Antimicrob. Agents Chemother.* 53, 1501–1508.
- Chiba, N., Osada, M., Komoro, K., Mizutani, T., Kariwa, H., Takashima, I., 1999. Protection against tick-borne encephalitis virus isolated in Japan by active and passive immunization. *Vaccine* 17, 1532–1539.
- Choi, K.S., Nah, J.J., Ko, Y.J., Kim, Y.J., Joo, Y.S., 2007. The DE loop of the domain III of the envelope protein appears to be associated with West Nile virus neutralization. *Virus Res.* 123, 216–218.
- Chowers, M.Y., Lang, R., Nassar, F., Ben-David, D., Giladi, M., Rubinshtein, E., Itzhaki, A., Mishal, J., Siegman-Igra, Y., Kitzes, R., Pick, N., Landau, Z., Wolf, D., Bin, H., Mendelson, E., Pitlik, S.D., Weinberger, M., 2001. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. *Emerg. Infect. Dis.* 7, 675–678.
- Chu, J.J., Ng, M.L., 2004a. Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. *J. Virol.* 78, 10543–10555.
- Chu, J.J., Ng, M.L., 2004b. Interaction of West Nile virus with α v β 3 integrin mediates virus entry into cells. *J. Biol. Chem.* 279, 54533–54541.
- Chung, K.M., Nybakken, G.E., Thompson, B.S., Engle, M.J., Marri, A., Fremont, D.H., Diamond, M.S., 2006. Antibodies against West Nile virus non-structural (NS)-1 protein prevent lethal infection through Fc gamma receptor-dependent and independent mechanisms. *J. Virol.* 80, 1340–1351.
- Chung, K.M., Thompson, B.S., Fremont, D.H., Diamond, M.S., 2007. Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor mediated phagocytosis and clearance of WNV infected cells. *J. Virol.* 81, 9551–9555.
- Colombage, G., Hall, R., Pavy, M., Lobigs, M., 1998. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. *Virology* 250, 151–163.
- Colonna, M., 2007. TLR pathways and IFN-regulatory factors: to each its own. *Eur. J. Immunol.* 37, 306–309.
- Courageot, M.P., Frenkiel, M.P., Dos Santos, C.D., Deubel, V., Despres, P., 2000. Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. *J. Virol.* 74, 564–572.
- Crance, J.M., Scaramozzino, N., Jouan, A., Garin, D., 2003. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. *Antiviral Res.* 58, 73–79.
- Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R., Cameron, C.E., 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. *Nat. Med.* 6, 1375–1379.
- Daffis, S., Samuel, M.A., Keller, B.C., Gale Jr., M., Diamond, M.S., 2007. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and independent mechanisms. *PLoS Pathog.* 3, e106.
- Daffis, S., Samuel, M.A., Suthar, M.S., Gale Jr., M., Diamond, M.S., 2008a. Toll-like receptor 3 has a protective role against West Nile virus infection. *J. Virol.* 82, 10349–10358.
- Daffis, S., Samuel, M.A., Suthar, M.S., Keller, B.C., Gale Jr., M., Diamond, M.S., 2008b. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. *J. Virol.* 82, 8465–8475.
- Dai, J., Wang, P., Bai, F., Town, T., Fikrig, E., 2008. ICAM-1 participates in the entry of West Nile virus into the central nervous system. *J. Virol.* 82, 4164–4168.
- Davis, C.W., Nguyen, H.Y., Hanna, S.L., Sanchez, M.D., Doms, R.W., Pierson, T.C., 2006. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. *J. Virol.* 80, 1290–1301.
- Davis, G.L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S.C., Trepo, C., Shiffman, M.L., Zeuzem, S., Craxi, A., Ling, M.H., Albrecht, J., 1998. Interferon α -2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N. Engl. J. Med.* 339, 1493–1499.
- Day, C.W., Smeets, D.F., Julander, J.G., Yamshchikov, V.F., Sidwell, R.W., Morrey, J.D., 2005. Error-prone replication of West Nile virus caused by ribavirin. *Antiviral Res.* 67, 38–45.
- Deas, T.S., Bennett, C.J., Jones, S.A., Tilgner, M., Ren, P., Behr, M.J., Stein, D.A., Iversen, P.L., Kramer, L.D., Bernard, K.A., Shi, P.Y., 2007. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. *Antimicrob. Agents Chemother.* 51, 2470–2482.
- Deas, T.S., Binduga-Gajewska, I., Tilgner, M., Ren, P., Stein, D.A., Moulton, H.M., Iversen, P.L., Kauffman, E.B., Kramer, L.D., Shi, P.Y., 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. *J. Virol.* 79, 4599–4609.
- DeSalvo, D., Roy-Chaudhury, P., Peddi, R., Merchen, T., Konijetti, K., Gupta, M., Boardman, R., Rogers, C., Buell, J., Hanaway, M., Broderick, J., Smith, R., Woodlee, E.S., 2004. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. *Transplantation* 77, 466–469.
- Despres, P., Dietrich, J., Girard, M., Bouloy, M., 1991. Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice. *J. Gen. Virol.* 72 (Pt 11), 2811–2816.
- Diamond, M.S., 2003. Evasion of innate and adaptive immunity by flaviviruses. *Immunol. Cell Biol.* 81, 196–206.
- Diamond, M.S., Harris, E., 2001. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. *Virology* 289, 297–311.
- Diamond, M.S., Mehlhop, E., Oliphant, T., Samuel, M.A., 2009. The host immunologic response to West Nile encephalitis virus. *Front. Biosci.* 14, 3024–3034.
- Diamond, M.S., Roberts, T., Edgil, D., Lu, B., Ernst, J., Harris, E., 2000. Modulation of dengue virus infection in human cells by α , β , and γ interferons. *J. Virol.* 74, 4957–4966.
- Diamond, M.S., Shrestha, B., Marri, A., Mahan, D., Engle, M., 2003a. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. *J. Virol.* 77, 2578–2586.
- Diamond, M.S., Sitati, E., Friend, L., Shrestha, B., Higgs, S., Engle, M., 2003b. Induced IgM protects against lethal West Nile virus infection. *J. Exp. Med.* 198, 1–11.
- Diamond, M.S., Zachariah, M., Harris, E., 2002. Mycophenolic Acid inhibits dengue virus infection by preventing replication of viral RNA. *Virology* 304, 211–221.
- Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S., Reis e Sousa, C., 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science* 303, 1529–1531.

- Dong, H., Zhang, B., Shi, P.Y., 2008. Flavivirus methyltransferase: a novel antiviral target. *Antiviral Res.* 80, 1–10.
- Douglas, M.W., Kesson, A.M., King, N.J., 1994. CTL recognition of west Nile virus-infected fibroblasts is cell cycle dependent and is associated with virus-induced increases in class I MHC antigen expression. *Immunology* 82, 561–570.
- Eldadah, A.H., Nathanson, N., 1967. Pathogenesis of West Nile Virus encephalitis in mice and rats. II. Virus multiplication, evolution of immunofluorescence, and development of histological lesions in the brain. *Am. J. Epidemiol.* 86, 776–790.
- Eldadah, A.H., Nathanson, N., Sarsitis, R., 1967. Pathogenesis of West Nile Virus encephalitis in mice and rats. I. Influence of age and species on mortality and infection. *Am. J. Epidemiol.* 86, 765–775.
- Elshuber, S., Allison, S.L., Heinz, F.X., Mandl, C.W., 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. *J. Gen. Virol.* 84, 183–191.
- Engle, M., Diamond, M.S., 2003. Antibody prophylaxis and therapy against West Nile Virus infection in wild type and immunodeficient mice. *J. Virol.* 77, 12941–12949.
- Evans, J.D., Seeger, C., 2007. Differential effects of mutations in NS4B on WNV replication and inhibition of interferon signaling. *J. Virol.* 81, 11809–11816.
- Falconar, A.K., 1999. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. *Arch. Virol.* 144, 2313–2330.
- Falgout, B., Bray, M., Schlesinger, J.J., Lai, C.J., 1990. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. *J. Virol.* 64, 4356–4363.
- Feng, J.Q., Mozdanzowska, K., Gerhard, W., 2002. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. *J. Virol.* 76, 1369–1378.
- Fredericksen, B.L., Gale Jr., M., 2006. West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. *J. Virol.* 80, 2913–2923.
- Fredericksen, B.L., Keller, B.C., Fornek, J., Katze, M.G., Gale Jr., M., 2008. Establishment and maintenance of the innate antiviral response to West Nile virus involves both RIG-I and MDA5 signaling through IPS-1. *J. Virol.* 82, 609–616.
- Fredericksen, B.L., Smith, M., Katze, M.G., Shi, P.Y., Gale, M., 2004. The host response to West Nile virus infection limits spread through the activation of the interferon regulatory factor 3 pathway. *J. Virol.* 78, 7737–7747.
- Geiss, B.J., Pierson, T.C., Diamond, M.S., 2005. Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA. *Virol. J.* 2 (53), 1–13.
- Getts, D.R., Terry, R.L., Getts, M.T., Muller, M., Rana, S., Shrestha, B., Radford, J., Van Rooijen, N., Campbell, I.L., King, N.J., 2008. Ly6c+ “inflammatory monocytes” are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. *J. Exp. Med.* 205, 2319–2337.
- Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R.A., Diamond, M.S., Colonna, M., 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. *Proc. Natl. Acad. Sci. U.S.A.* 103, 8459–8464.
- Glass, J.D., Samuels, O., Rich, M.M., 2002. Poliomyelitis due to West Nile virus. *N. Engl. J. Med.* 347, 1280–1281.
- Glass, W.G., Lim, J.K., Cholera, R., Pletnev, A.G., Gao, J.L., Murphy, P.M., 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. *J. Exp. Med.* 202, 1087–1098.
- Glass, W.G., McDermott, D.H., Lim, J.K., Lekhong, S., Yu, S.F., Frank, W.A., Pape, J., Cheshier, R.C., Murphy, P.M., 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. *J. Exp. Med.* 203, 35–40.
- Gollins, S., Porterfield, J., 1984. Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody and viral fate. *J. Gen. Virol.* 65, 1261–1272.
- Gollins, S., Porterfield, J., 1986. The uncoating and infectivity of the flavivirus West Nile on interaction with cells: effects of pH and ammonium chloride. *J. Gen. Virol.* 67, 1941–1950.
- Gollins, S.W., Porterfield, J.S., 1985. Flavivirus infection enhancement in macrophages: an electron microscopic study of viral entry. *J. Gen. Virol.* 66, 1969–1982.
- Gonzalez, A.P., Chien, C.H., Tubthong, K., Gorshkova, I., Roll, C., Donau, O., Schuck, P., Yoksan, S., Wang, S.D., Purcell, R.H., Lai, C.J., 2008. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. *J. Virol.* 82, 7009–7021.
- Gonzalez, A.P., Engle, R.E., St Claire, M., Purcell, R.H., Lai, C.J., 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. *Proc. Natl. Acad. Sci. U.S.A.* 104, 9422–9427.
- Gong, Z.J., De Meyer, S., Clarysse, C., Verslype, C., Neyts, J., De Clercq, E., Yap, S.H., 1999. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. *J. Viral Hepat.* 6, 229–236.
- Goodell, J.R., Puig-Basagoiti, F., Forshey, B.M., Shi, P.Y., Ferguson, D.M., 2006. Identification of compounds with anti-West Nile Virus activity. *J. Med. Chem.* 49, 2127–2137.
- Gould, E.A., B.B.K.G., Cane, P.A., Doenhoff, M., 1987. Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. *J. Gen. Virol.* 68, 3105–3112.
- Gould, E.A., Buckley, A., 1989. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. *J. Gen. Virol.* 70, 1605–1608.
- Gould, L.H., Sui, J., Foellmer, H., Oliphant, T., Wang, T., Ledizet, M., Murakami, A., Noonan, K., Lambeth, C., Kar, K., Anderson, J.F., de Silva, A.M., Diamond, M.S., Koski, R.A., Marasco, W.A., Filkrig, E., 2005. Protective and therapeutic capacity of human single chain Fv-Fc fusion proteins against West Nile virus. *J. Virol.* 79, 14606–14613.
- Granwehr, B.P., Lillibridge, K.M., Higgs, S., Mason, P.W., Aronson, J.F., Campbell, G.A., Barrett, A.D., 2004. West Nile virus: where are we now? *Lancet Infect. Dis.* 4, 547–556.
- Gromowski, G.D., Barrett, A.D., 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. *Virology* 366, 349–360.
- Gu, B., Mason, P., Wang, L., Norton, P., Bourne, N., Moriarty, R., Mehta, A., Deshpande, M., Shah, R., Block, T., 2007. Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhoea virus, West Nile virus, dengue virus and hepatitis B virus. *Antivir. Chem. Chemother.* 18, 49–59.
- Gu, B., Ouzunov, S., Wang, L., Mason, P., Bourne, N., Cuconati, A., Block, T.M., 2006. Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen. *Antiviral Res.* 70, 39–50.
- Guirakhoo, F., Bolin, R.A., Roehrig, J.T., 1992. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. *Virology* 191, 921–931.
- Halevy, M., Akov, Y., Ben-Nathan, D., Kobiler, D., Lachmi, B., Lustig, S., 1994. Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice. *Arch. Virol.* 137, 355–370.
- Haley, M., Retter, A.S., Fowler, D., Gea-Banacloche, J., O’Grady, N.P., 2003. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. *Clin. Infect. Dis.* 37, e88–e90.
- Hall, C.B., McBride, J.T., Walsh, E.E., Bell, D.M., Gala, C.L., Hildreth, S., Ten Eyck, L.G., Hall, W.J., 1983. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection, A randomized double-blind study. *N. Engl. J. Med.* 308, 1443–1447.
- Halstead, S.B., 1989. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. *Rev. Infect. Dis.* 11 (Suppl. 4), S830–S839.
- Halstead, S.B., Porterfield, J.S., O’Rourke, E.J., 1980. Enhancement of dengue virus infection in monocytes by flavivirus antisera. *Am. J. Trop. Med. Hyg.* 29, 638–642.
- Hamdan, A., Green, P., Mendelson, E., Kramer, M.R., Pitlik, S., Weinberger, M., 2002. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. *Transpl. Infect. Dis.* 4, 160–162.
- Hebelle, T., Ahearn, J.M., Fearon, D.T., 1991. Suppression of the immune response by a soluble complement receptor of B lymphocytes. *Science* 254, 102–105.
- Henchal, E.A., Henchal, L.S., Schlesinger, J.J., 1988. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. *J. Gen. Virol.* 69 (Pt 8), 2101–2107.
- Higgs, S., Schneider, B.S., Vanlandingham, D.L., Klingler, K.A., Gould, E.A., 2005. Nonviremic transmission of West Nile virus. *Proc. Natl. Acad. Sci. U.S.A.* 102, 8871–8874.
- Hiramatsu, K., Tadano, M., Men, R., Lai, C.J., 1996. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DENV2) envelope protein: monoclonal antibody resistant DENV2/DENV4 chimeras exhibit reduced mouse neurovirulence. *Virology* 224, 437–445.
- Ho, L.J., Wang, J.J., Shaio, M.F., Kao, C.L., Chang, D.M., Han, S.W., Lai, J.H., 2001. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. *J. Immunol.* 166, 1499–1506.
- Hornung, V., Barchet, W., Schlee, M., Hartmann, G., 2008. RNA recognition via TLR7 and TLR8. *Handb. Exp. Pharmacol.* 71–86.
- Hrobowski, Y.M., Garry, R.F., Michael, S.F., 2005. Peptide inhibitors of dengue virus and West Nile virus infectivity. *Virol. J.* 2, 49.
- Hubalek, Z., Halouzka, J., 1999. West Nile fever—a reemerging mosquito-borne viral disease in Europe. *Emerg. Infect. Dis.* 5, 643–650.
- Huggins, J.W., Hsiang, C.M., Cosgriff, T.M., Guang, M.Y., Smith, J.I., Wu, Z.O., LeDuc, J.W., Zheng, Z.M., Meegan, J.M., Wang, Q.N., et al., 1991. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. *J. Infect. Dis.* 164, 1119–1127.
- Huhn, G.D., Austin, C., Langkop, C., Kelly, K., Lucht, R., Lampman, R., Novak, R., Haramis, L., Boker, R., Smith, S., Chudoba, M., Gerber, S., Conover, C., Dworkin, M.S., 2005. The Emergence of West Nile Virus During a large outbreak in Illinois in 2002. *Am. J. Trop. Med. Hyg.* 72, 768–776.
- Iankov, I.D., Pandey, M., Harvey, M., Griesmann, G.E., Federspiel, M.J., Russell, S.J., 2006. Immunoglobulin G antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. *J. Virol.* 80, 8530–8540.
- Ichimura, H., Levy, J.A., 1995. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. *Virology* 211, 554–560.
- Jackson, A.C., 2004. Therapy of West Nile virus infection. *Can. J. Neurol. Sci.* 31, 131–134.
- Jester, P.M., Tilden, S.J., Li, Y., Whitley, R.J., Sullender, W.M., 2006. Regulatory challenges: lessons from recent West Nile virus trials in the United States. *Contemp. Clin. Trials* 27, 254–259.
- Johnson, R.T., Mims, C.A., 1968. Pathogenesis of viral infections of the nervous system. *N. Engl. J. Med.* 278, 23–30 (contd).
- Johnston, L.J., Halliday, G.M., King, N.J., 2000. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. *J. Invest. Dermatol.* 114, 560–568.
- Johnston, P.A., Phillips, J., Shun, T.Y., Shinde, S., Lazo, J.S., Huryn, D.M., Myers, M.C., Ratnikov, B.I., Smith, J.W., Su, Y., Dahl, R., Cosford, N.D., Shiryayev, S.A., Strongin, A.Y., 2007. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B–NS3 proteinase of West Nile virus. *Assay Drug Dev. Technol.* 5, 737–750.

- Jones, M., Davidson, A., Hibbert, L., Gruenwald, P., Schlaak, J., Ball, S., Foster, G.R., Jacobs, M., 2005. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. *J. Virol.* 79, 5414–5420.
- Jordan, I., Briese, T., Fischer, N., Lau, J.Y., Lipkin, W.I., 2000. Ribavirin inhibits west nile virus replication and cytopathic effect in neural cells. *J. Infect. Dis.* 182, 1214–1217.
- Julander, J.G., Winger, Q.A., Olsen, A.L., Day, C.W., Sidwell, R.W., Morrey, J.D., 2005. Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival. *Antiviral Res.* 65, 79–85.
- Kalil, A.C., Devetten, M.P., Singh, S., Lesiak, B., Poage, D.P., Bargenquast, K., Fayad, P., Freifeld, A.G., 2005. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. *Clin. Infect. Dis.* 40, 764–766.
- Kanai, R., Kar, K., Anthony, K., Gould, L.H., Ledizet, M., Fikrig, E., Marasco, W.A., Koski, R.A., Modis, Y., 2006. Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. *J. Virol.* 80, 11000–11008.
- Kapoor, H., Signs, K., Somsel, P., Downes, F.P., Clark, P.A., Massey, J.P., 2004. Persistence of West Nile Virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease. *J. Clin. Virol.* 31, 289–291.
- Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., Yamaguchi, O., Otsu, K., Tsujimura, T., Koh, C.S., Reis e Sousa, C., Matsuura, Y., Fujita, T., Akira, S., 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 441, 101–105.
- Kawai, T., Akira, S., 2006. Innate immune recognition of viral infection. *Nat. Immunol.* 7, 131–137.
- Kiberd, B.A., Forward, K., 2004. Screening for West Nile virus in organ transplantation: a medical decision analysis. *Am. J. Transplant.* 4, 1296–1301.
- Kilpatrick, A.M., Kramer, L.D., Jones, M.J., Marra, P.P., Daszak, P., 2006. West Nile virus epidemics in North America are driven by shifts in mosquito feeding behavior. *PLoS Biol.* 4, e82.
- Kim, H., Yang, E., Lee, J., Kim, S.H., Shin, J.S., Park, J.Y., Choi, S.J., Kim, S.J., Choi, I.H., 2008. Double-stranded RNA mediates interferon regulatory factor 3 activation and interleukin-6 production by engaging Toll-like receptor 3 in human brain astrocytes. *Immunology* 124, 480–488.
- Kimura-Kuroda, J., Yasui, K., 1988. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. *J. Immunol.* 141, 3606–3610.
- King, N.J., Kesson, A.M., 1988. Interferon-independent increases in class I major histocompatibility complex antigen expression follow flavivirus infection. *J. Gen. Virol.* 69, 2535–2543.
- King, N.J., Kesson, A.M., 2003. Interaction of flaviviruses with cells of the vertebrate host and decoy of the immune response. *Immunol. Cell Biol.* 81, 207–216.
- King, N.J., Maxwell, L.E., Kesson, A.M., 1989. Induction of class I major histocompatibility complex antigen expression by West Nile virus on gamma interferon-refractory early murine trophoblast cells. *Proc. Natl. Acad. Sci. U.S.A.* 86, 911–915.
- Kinney, R.M., Huang, C.Y., Rose, B.C., Kroeker, A.D., Dreher, T.W., Iversen, P.L., Stein, D.A., 2005. Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers. *J. Virol.* 79, 5116–5128.
- Kleinman, S.H., Williams, J.D., Robertson, G., Caglioti, S., Williams, R.C., Spizman, R., Morgan, L., Tomasulo, P., Busch, M.P., 2009. West Nile virus testing experience in 2007: evaluation of different criteria for triggering individual-donation nucleic acid testing. *Transfusion*, in press.
- Kleinschmidt-DeMasters, B.K., Marder, B.A., Levi, M.E., Laird, S.P., McNutt, J.T., Escott, E.J., Everson, G.T., Tyler, K.L., 2004. Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. *Arch. Neurol.* 61, 1210–1220.
- Komar, N., 2003. West Nile virus: epidemiology and ecology in North America. *Adv. Virus Res.* 61, 185–234.
- Kreil, T.R., Eibl, M.M., 1996. Nitric oxide and viral infection: NO antiviral activity against a flavivirus in vitro, and evidence for contribution to pathogenesis in experimental infection in vivo. *Virology* 219, 304–306.
- Kreil, T.R., Eibl, M.M., 1997. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. *J. Virol.* 71, 2921–2927.
- Krishnan, M.N., Sukumaran, B., Pal, U., Agaisse, H., Murray, J.L., Hodge, T.W., Fikrig, E., 2007. Rab 5 is required for the cellular entry of dengue and West Nile viruses. *J. Virol.* 81, 4881–4885.
- Kuhn, R.J., Zhang, W., Rossmann, M.G., Pletnev, S.V., Corver, J., Lenches, E., Jones, C.T., Mukhopadhyay, S., Chipman, P.R., Strauss, E.G., Baker, T.S., Strauss, J.H., 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. *Cell* 108, 717–725.
- Kumar, D., Drebort, M.A., Wong, S.J., Lim, G., Artsob, H., Buck, P., Humar, A., 2004a. A seroprevalence study of west nile virus infection in solid organ transplant recipients. *Am. J. Transplant.* 4, 1883–1888.
- Kumar, D., Prasad, G.V., Zaltzman, J., Levy, G.A., Humar, A., 2004b. Community-acquired West Nile virus infection in solid-organ transplant recipients. *Transplantation* 77, 399–402.
- Kumar, P., Lee, S.K., Shankar, P., Manjunath, N., 2006. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. *PLoS Med.* 3, e96.
- Kurane, I., Ennis, F.E., 1992. Immunity and immunopathology in dengue virus infections. *Semin. Immunol.* 4, 121–127.
- Lai, C.J., Gonzalez, A.P., Men, R., Wernly, C., Donau, O., Engle, R.E., Purcell, R.H., 2007. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. *J. Virol.* 81, 12766–12774.
- Lang, L., 2007. The Food and Drug Administration approves second West Nile virus screening test for donated blood and organs. *Gastroenterology* 133, 1402.
- Leis, A.A., Frattin, J., Stokic, D.S., Harrington, T., Webb, R.M., Slavinski, S.A., 2003. West Nile poliomyelitis. *Lancet Infect. Dis.* 3, 9–10.
- Leis, A.A., Stokic, D.S., Polk, J.L., Dostrow, V., Winkelmann, M., 2002. A poliomyelitis-like syndrome from West Nile virus infection. *N. Engl. J. Med.* 347, 1279–1280.
- Lescar, J., Roussel, A., Wien, M.W., Navaza, J., Fuller, S.D., Wengler, G., Rey, F.A., 2001. The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. *Cell* 105, 137–148.
- Lewis, M., Amsden, J.R., 2007. Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course. *Pharmacotherapy* 27, 455–458.
- Leyssen, P., Balzarini, J., De Clercq, E., Neyts, J., 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. *J. Virol.* 79, 1943–1947.
- Li, L., Barrett, A.D., Beasley, D.W., 2005. Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. *Virology* 335, 99–105.
- Libraty, D.H., Pichyangkul, S., Ajariyakhajorn, C., Endy, T.P., Ennis, F.A., 2001. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. *J. Virol.* 75, 3501–3508.
- Lim, J.K., Lisco, A., McDermott, D.H., Huynh, L., Ward, J.M., Johnson, B., Johnson, H., Pape, J., Foster, G.A., Krysztof, D., Follmann, D., Stramer, S.L., Margolis, L.B., Murphy, P.M., 2009. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. *PLoS Pathog.* 5, e1000321.
- Lin, C.W., Cheng, C.W., Yang, T.C., Li, S.W., Cheng, M.H., Wan, L., Lin, Y.J., Lai, C.H., Lin, W.Y., Kao, M.C., 2008. Interferon antagonist function of Japanese encephalitis virus NS4A and its interaction with DEAD-box RNA helicase DDX42. *Virus Res.* 137, 49–55.
- Lin, R.J., Liao, C.L., Lin, E., Lin, Y.L., 2004. Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese Encephalitis Virus. *J. Virol.* 78, 9285–9294.
- Lin, Y.L., Huang, Y.L., Ma, S.H., Yeh, C.T., Chiou, S.Y., Chen, L.K., Liao, C.L., 1997. Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. *J. Virol.* 71, 5227–5235.
- Lindenbach, B.D., Rice, C.M., Flaviviridae: The viruses and their replication 2001. In: Knipe, D.M., Howley, P.M. (Eds.), *Fields Virology*, vol. 1. Lippincott Williams & Wilkins, Philadelphia, pp. 991–1041.
- Liu, W.J., Chen, H.B., Wang, X.J., Huang, H., Khromykh, A.A., 2004. Analysis of adaptive mutations in kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. *J. Virol.* 78, 12225–12235.
- Liu, W.J., Wang, X.J., Clark, D.C., Lobigs, M., Hall, R.A., Khromykh, A.A., 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. *J. Virol.* 80, 2396–2404.
- Liu, W.J., Wang, X.J., Mokhonov, V.V., Shi, P.Y., Randall, R., Khromykh, A.A., 2005. Inhibition of interferon signaling by the New York 99 strain and kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. *J. Virol.* 79, 1934–1942.
- Liu, Y., King, N., Kesson, A., Blanden, R.V., Mullbacher, A., 1988. West Nile virus infection modulates the expression of class I and class II MHC antigens on astrocytes in vitro. *Ann. N.Y. Acad. Sci.* 540, 483–485.
- Ma, D.D., Rede, T., Naqvi, N.A., Cook, P.D., 2000. Synthetic oligonucleotides as therapeutics: the coming of age. *Biotechnol. Annu. Rev.* 5, 155–196.
- Mackenzie, J.M., Westaway, E.G., 2001. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. *J. Virol.* 75, 10787–10799.
- Marovich, M., Grouard-Vogel, G., Louder, M., Eller, M., Sun, W., Wu, S.J., Putvatana, R., Murphy, G., Tassaneerithee, B., Burgess, T., Birx, D., Hayes, C., Schlesinger-Frankel, S., Mascola, J., 2001. Human dendritic cells as targets of dengue virus infection. *J. Invest. Dermatol. Symp. Proc.* 6, 219–224.
- Martin, D.A., Noga, A., Kosoy, O., Johnson, A.J., Petersen, L.R., Lanciotti, R.S., 2004. Evaluation of a diagnostic algorithm using immunoglobulin M enzyme-linked immunosorbent assay to differentiate human West Nile Virus and St. Louis Encephalitis virus infections during the 2002 West Nile Virus epidemic in the United States. *Clin. Diagn. Lab. Immunol.* 11, 1130–1133.
- McCormick, J.B., King, I.J., Webb, P.A., Scribner, C.L., Craven, R.B., Johnson, K.M., Elliott, L.H., Belmont-Williams, R., 1986. Lassa fever. Effective therapy with ribavirin. *N. Engl. J. Med.* 314, 20–26.
- McCown, M., Diamond, M.S., Pekosz, A., 2003. The utility of siRNA transcripts produced by RNA polymerase I in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. *Virology* 313, 514–524.
- McJunkin, J.E., Khan, R., de los Reyes, E.C., Parsons, D.L., Minnich, L.L., Ashley, R.G., Tsai, T.F., 1997. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. *Pediatrics* 99, 261–267.
- Medigeshi, G.R., Hirsch, A.J., Streblow, D.N., Nikolich-Zugich, J., Nelson, J.A., 2008. West Nile virus entry requires cholesterol-rich membrane microdomains and is independent of alphavbeta3 integrin. *J. Virol.* 82, 5212–5219.
- Medigeshi, G.R., Lancaster, A.M., Hirsch, A.J., Briese, T., Lipkin, W.I., Defilippis, V., Fruh, K., Mason, P.W., Nikolich-Zugich, J., Nelson, J.A., 2007. West Nile virus infection activates the unfolded protein response leading to CHOP induction and apoptosis. *J. Virol.* 81, 10849–10860.
- Mehlhof, E., Ansarah-Sobrinho, C., Johnson, S., Engle, M., Fremont, D.H., Pierson, T.C., Diamond, M.S., 2007. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. *Cell Host Microbe* 2, 417–426.

- Mehlhop, E., Diamond, M.S., 2006. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. *J. Exp. Med.* 203, 1371–1381.
- Mehlhop, E., Whitby, K., Oliphant, T., Marri, A., Engle, M., Diamond, M.S., 2005. Complement activation is required for the induction of a protective antibody response against West Nile virus infection. *J. Virol.* 79, 7466–7477.
- Meister, G., Landthaler, M., Dorsett, Y., Tuschl, T., 2004. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. *RNA* 10, 544–550.
- Modis, Y., Ogata, S., Clements, D., Harrison, S.C., 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. *Proc. Natl. Acad. Sci. U.S.A.* 100, 6986–6991.
- Modis, Y., Ogata, S., Clements, D., Harrison, S.C., 2004. Structure of the dengue virus envelope protein after membrane fusion. *Nature* 427, 313–319.
- Morens, D.M., 1994. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. *Clin. Infect. Dis.* 19, 500–512.
- Morrey, J.D., Day, C.W., Julander, J.G., Blatt, L.M., Smeets, D.F., Sidwell, R.W., 2004. Effect of interferon- α and interferon-inducers on West Nile virus in mouse and hamster animal models. *Antivir. Chem. Chemother.* 15, 101–109.
- Morrey, J.D., Siddharthan, V., Olsen, A.L., Roper, G.Y., Wang, H., Baldwin, T.J., Koenig, S., Johnson, S., Nordstrom, J.L., Diamond, M.S., 2006. Humanized monoclonal antibody against West Nile virus E protein administered after neuronal infection protects against lethal encephalitis in hamsters. *J. Infect. Dis.* 194, 1300–1308.
- Morrey, J.D., Siddharthan, V., Olsen, A.L., Wang, H., Julander, J.G., Hall, J.O., Li, H., Nordstrom, J.L., Koenig, S., Johnson, S., Diamond, M.S., 2007. Defining limits of humanized neutralizing monoclonal antibody treatment for West Nile virus neurological infection in a hamster model. *Antimicrob. Agents Chemother.* 51, 2396–2402.
- Morrey, J.D., Siddharthan, V., Wang, H., Hall, J.O., Skirpstunas, R.T., Olsen, A.L., Nordstrom, J.L., Koenig, S., Johnson, S., Diamond, M.S., 2008a. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. *J. Neurovirol.* 14, 152–163.
- Morrey, J.D., Smeets, D.F., Sidwell, R.W., Tseng, C., 2002. Identification of active antiviral compounds against a New York isolate of West Nile virus. *Antiviral Res.* 55, 107–116.
- Morrey, J.D., Taro, B.S., Siddharthan, V., Wang, H., Smeets, D.F., Christensen, A.J., Furuta, Y., 2008b. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. *Antiviral Res.* 80, 377–379.
- Mostashari, F., Bunning, M.L., Kitsutani, P.T., Singer, D.A., Nash, D., Cooper, M.J., Katz, N., Liljebjelke, K.A., Biggerstaff, B.J., Fine, A.D., Layton, M.C., Mullin, S.M., Johnson, A.J., Martin, D.A., Hayes, E.B., Campbell, G.L., 2001. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. *Lancet* 358, 261–264.
- Mozdzanowska, K., Feng, J., Eid, M., Zharkova, D., Gerhard, W., 2006. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. *Virology* 352, 418–426.
- Mueller, N.H., Pattabiraman, N., Ansarah-Sobrinho, C., Viswanathan, P., Pierson, T.C., Padmanabhan, R., 2008. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. *Antimicrob. Agents Chemother.* 52, 3385–3393.
- Mukhopadhyay, S., Kim, B.S., Chipman, P.R., Rossmann, M.G., Kuhn, R.J., 2003. Structure of West Nile virus. *Science* 302, 248.
- Mukhopadhyay, S., Kuhn, R.J., Rossmann, M.G., 2005. A structural perspective of the flavivirus life cycle. *Nat. Rev. Microbiol.* 3, 13–22.
- Munoz-Jordan, J.L., Laurent-Rolle, M., Ashour, J., Martinez-Sobrido, L., Ashok, M., Lipkin, W.I., Garcia-Sastre, A., 2005. Inhibition of α/β interferon signaling by the NS4B protein of flaviviruses. *J. Virol.* 79, 8004–8013.
- Munoz-Jordan, J.L., Sanchez-Burgos, G.G., Laurent-Rolle, M., Garcia-Sastre, A., 2003. Inhibition of interferon signaling by dengue virus. *Proc. Natl. Acad. Sci. U.S.A.* 100, 14333–14338.
- Murray, K., Baraniuk, S., Resnick, M., Arafat, R., Kilborn, C., Cain, K., Shallenberger, R., York, T.L., Martinez, D., Hellums, J.S., Hellums, D., Malkoff, M., Elgawley, N., McNeely, W., Khuwaja, S.A., Tesh, R.B., 2006. Risk factors for encephalitis and death from West Nile virus infection. *Epidemiol. Infect.* 134, 1325–1332.
- Nagy, S.E., Andersson, J.P., Andersson, U.G., 1993. Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines. *Immunopharmacology* 26, 11–20.
- Nash, D., Mostashari, F., Fine, A., Miller, J., O'Leary, D., Murray, K., Huang, A., Rosenberg, A., Greenberg, A., Sherman, M., Wong, S., Layton, M., 2001. The outbreak of West Nile virus infection in the New York City area in 1999. *N. Engl. J. Med.* 344, 1807–1814.
- Neuman, B.W., Stein, D.A., Kroeker, A.D., Paulino, A.D., Moulton, H.M., Iversen, P.L., Buchmeier, M.J., 2004. Antisense morpholino-oligonucleotides directed against the 5' end of the genome inhibit coronavirus proliferation and growth. *J. Virol.* 78, 5891–5899.
- Neyts, J., De Clercq, E., 1998. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. *Antiviral Res.* 40, 53–56.
- Ng, C.Y., Gu, F., Phong, W.Y., Chen, Y.L., Lim, S.P., Davidson, A., Vasudevan, S.G., 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. *Antiviral Res.* 76, 222–231.
- Nouiery, A.O., Olivo, P.D., Slomczynska, U., Zhou, Y., Buscher, B., Geiss, B., Engle, M., Roth, R.M., Chung, K.M., Samuel, M.A., Diamond, M.S., 2007. The identification of novel small molecule inhibitors of West Nile virus infection. *J. Virol.* 81, 11992–12004.
- Nybakken, G., Oliphant, T., Johnson, S., Burke, S., Diamond, M.S., Fremont, D.H., 2005. Structural basis for neutralization of a therapeutic antibody against West Nile virus. *Nature* 437, 764–769.
- Nybakken, G.E., Nelson, C.A., Chen, B.R., Diamond, M.S., Fremont, D.H., 2006. Crystal structure of the West Nile virus envelope glycoprotein. *J. Virol.* 80, 11467–11474.
- Okazaki, K., Kida, H., 2004. A synthetic peptide from a heptad repeat region of herpesvirus glycoprotein B inhibits virus replication. *J. Gen. Virol.* 85, 2131–2137.
- Oliphant, T., Engle, M., Nybakken, G., Doane, C., Johnson, S., Huang, L., Gorlatov, S., Mehlhop, E., Marri, A., Chung, K.M., Ebel, G.D., Kramer, L.D., Fremont, D.H., Diamond, M.S., 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. *Nat. Med.* 11, 522–530.
- Ong, S.P., Chu, J.J., Ng, M.L., 2008. Inhibition of West Nile virus replication in cells stably transfected with vector-based shRNA expression system. *Virus Res.* 135, 292–297.
- Pealer, L.N., Marfin, A.A., Petersen, L.R., Lanciotti, R.S., Page, P.L., Stramer, S.L., Stobierski, M.G., Signs, K., Newman, B., Kapoor, H., Goodman, J.L., Chamberland, M.E., 2003. Transmission of West Nile virus through blood transfusion in the United States in 2002. *N. Engl. J. Med.* 349, 1236–1245.
- Peiris, J.S., Porterfield, J.S., 1979. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. *Nature* 282, 509–511.
- Peiris, J.S.M., Gordon, S., Unkles, J.C., Porterfield, J.S., 1981. Monoclonal anti-Fc receptor IgG blocks antibody-dependent enhancement of viral replication in macrophages. *Nature* 289, 189–191.
- Peiris, J.S.M., Porterfield, J.S., Roehrig, J.T., 1982. Monoclonal antibodies against the flavivirus West Nile. *J. Gen. Virol.* 58, 283–289.
- Petersen, L.R., Epstein, J.S., 2005. Problem solved? West Nile virus and transfusion safety. *N. Engl. J. Med.* 353, 516–517.
- Phillipotts, R.J., Stephenson, J.R., Porterfield, J.S., 1987. Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. *Brief report. Arch. Virol.* 93, 295–301.
- Pierson, T.C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G.E., Fremont, D.H., Diamond, M.S., 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. *Cell Host Microbe* 1, 135–145.
- Pincus, S., Mason, P.W., Konishi, E., Fonseca, B.A., Shope, R.E., Rice, C.M., Paoletti, E., 1992. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. *Virology* 187, 290–297.
- Prince, H.E., Lape-Nixon, M., Yeh, C., Tobler, L.H., Busch, M.P., 2008. Persistence of antibodies to West Nile virus nonstructural protein 5. *J. Clin. Virol.* 43, 102–106.
- Prince, H.E., Tobler, L.H., Yeh, C., Geffer, N., Custer, B., Busch, M.P., 2007. Persistence of West Nile virus-specific antibodies in viremic blood donors. *Clin. Vaccine Immunol.* 14, 1228–1230.
- Puig-Basagotti, F., Tilgner, M., Forshey, B.M., Philpott, S.M., Espina, N.G., Wentworth, D.E., Goebel, S.J., Masters, P.S., Falgout, B., Ren, P., Ferguson, D.M., Shi, P.Y., 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. *Antimicrob. Agents Chemother.* 50, 1320–1329.
- Purtha, W.E., Chachu, K.A., Virgin, H.W.t., Diamond, M.S., 2008. Early B-cell activation after West Nile virus infection requires α/β interferon but not antigen receptor signaling. *J. Virol.* 82, 10964–10974.
- Purtha, W.E., Myers, N., Mitaksov, V., Sitati, E., Connolly, J., Fremont, D.H., Hansen, T.H., Diamond, M.S., 2007. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. *Eur. J. Immunol.* 37, 1845–1854.
- Putnak, J.R., Schlesinger, J.J., 1990. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. *J. Gen. Virol.* 71 (Pt 8), 1697–1702.
- Rahal, J.J., Anderson, J., Rosenberg, C., Reagan, T., Thompson, L.L., 2004. Effect of interferon- $\alpha/2b$ therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. *J. Infect. Dis.* 190, 1084–1087.
- Ramanathan, M.P., Chambers, J.A., Pankhong, P., Chattergoon, M., Attatippaholkun, W., Dang, K., Shah, N., Weiner, D.B., 2006. Host cell killing by the West Nile Virus NS2B–NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. *Virology* 345, 56–72.
- Rapaport, D., Ovadia, M., Shai, Y., 1995. A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. *Embo J.* 14, 5524–5531.
- Raviprakash, K., Liu, K., Matteucci, M., Wagner, R., Riffenburgh, R., Carl, M., 1995. Inhibition of dengue virus by novel, modified antisense oligonucleotides. *J. Virol.* 69, 69–74.
- Rey, F.A., 2003. Dengue virus envelope glycoprotein structure: new insight into its interactions during viral entry. *Proc. Natl. Acad. Sci. U.S.A.* 100, 6899–6901.
- Rey, F.A., Heinz, F.X., Mandl, C., Kunz, C., Harrison, S.C., 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 Ångström resolution. *Nature* 375, 291–298.
- Roehrig, J.T., Mathews, J.H., Trent, D.W., 1983. Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. *Virology* 128, 118–126.
- Roehrig, J.T., Nash, D., Maldin, B., Labowitz, A., Martin, D.A., Lanciotti, R.S., Campbell, G.L., 2003. Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. *Emerg. Infect. Dis.* 9, 376–379.
- Roehrig, J.T., Staedinger, L.A., Hunt, A.R., Mathews, J.H., Blair, C.D., 2001. Antibody prophylaxis and therapy for flaviviral encephalitis infections. *Ann. N.Y. Acad. Sci.* 286–297.
- Samuel, C.E., 1991. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. *Virology* 183, 1–11.
- Samuel, M.A., Diamond, M.S., 2005. Type I IFN protects against lethal West Nile Virus infection by restricting cellular tropism and enhancing neuronal survival. *J. Virol.* 79, 13350–13361.

- Samuel, M.A., Diamond, M.S., 2006. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. *J. Virol.* 80, 9349–9360.
- Samuel, M.A., Morrey, J.D., Diamond, M.S., 2007a. Caspase-3 dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. *J. Virol.* 81, 2614–2623.
- Samuel, M.A., Wang, H., Siddharthan, V., Morrey, J.D., Diamond, M.S., 2007b. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. *Proc. Natl. Acad. Sci. U.S.A.* 104, 17140–17145.
- Samuel, M.A., Whitby, K., Keller, B.C., Marri, A., Barchet, W., Williams, B.R.G., Silverman, R.H., Gale, M., Diamond, M.S., 2006. PKR and RNase L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. *J. Virol.* 80, 7009–7019.
- Sanchez, M.D., Pierson, T.C., McAllister, D., Hanna, S.L., Puffer, B.A., Valentine, L.E., Murtadha, M.M., Hoxie, J.A., Doms, R.W., 2005. Characterization of neutralizing antibodies to West Nile virus. *Virology* 336, 70–82.
- Saqui, R., Randall, H., Chandrakantan, A., Spak, C.W., Barri, Y.M., 2008. West Nile virus encephalitis in a renal transplant recipient: the role of intravenous immunoglobulin. *Am. J. Kidney Dis.* 52, e19–21.
- Sawyer, L.A., 2000. Antibodies for the prevention and treatment of viral diseases. *Antiviral Res.* 47, 57–77.
- Sayao, A.L., Suchowersky, O., Al-Khatami, A., Klassen, B., Katz, N.R., Sevcik, R., Tilley, P., Fox, J., Patry, D., 2004. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. *Can. J. Neurol. Sci.* 31, 194–203.
- Schlesinger, J.J., Brandriss, M.W., Cropp, C.B., Monath, T.P., 1986. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. *J. Virol.* 60, 1153–1155.
- Schlesinger, J.J., Brandriss, M.W., Putnak, J.R., Walsh, E.E., 1990. Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody. *J. Gen. Virol.* 71 (Pt 3), 593–599.
- Schlesinger, J.J., Brandriss, M.W., Walsh, E.E., 1985. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. *J. Immunol.* 135, 2805–2809.
- Schlesinger, J.J., Brandriss, M.W., Walsh, E.E., 1987. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. *J. Gen. Virol.* 68 (Pt 3), 853–857.
- Schlesinger, J.J., Chapman, S., 1995. Neutralizing F(ab')₂ fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. *J. Gen. Virol.* 76 (Pt 1), 217–220.
- Schul, W., Liu, W., Xu, H.Y., Flamand, M., Vasudevan, S.G., 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. *J. Infect. Dis.* 195, 665–674.
- Sejvar, J.L., Haddad, M.B., Tierney, B.C., Campbell, G.L., Marfin, A.A., Van Gerpen, J.A., Fleischauer, A., Leis, A.A., Stokic, D.S., Petersen, L.R., 2003. Neurologic manifestations and outcome of West Nile virus infection. *JAMA* 290, 511–515.
- Shimoni, Z., Niven, M.J., Pitlick, S., Bulvik, S., 2001. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. *Emerg. Infect. Dis.* 7, 759.
- Shrestha, S., Kyle, J.L., Robert Beatty, P., Harris, E., 2004. Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. *Virology* 319, 262–273.
- Shrestha, B., Diamond, M.S., 2004. The role of CD8⁺ T cells in the control of West Nile virus infection. *J. Virol.* 78, 8312–8321.
- Shrestha, B., Gottlieb, D.L., Diamond, M.S., 2003. Infection and injury of neurons by West Nile Encephalitis virus. *J. Virol.* 77, 13203–13213.
- Shrestha, B., Samuel, M.A., Diamond, M.S., 2006a. CD8⁺ T cells require perforin to clear West Nile virus from infected neurons. *J. Virol.* 80, 119–129.
- Shrestha, B., Wang, T., Samuel, M.A., Whitby, K., Craft, J., Fikrig, E., Diamond, M.S., 2006b. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. *J. Virol.* 80, 5338–5348.
- Siddharthan, V., Wang, H., Motter, N.E., Hall, J.O., Skinner, R.D., Skirpstunas, R.T., Morrey, J.D., 2009. Persistent West Nile Virus associated with a neurological sequela in hamsters identified by motor unit number estimation. *J. Virol.* 83, 4251–4261.
- Sitati, E., Diamond, M.S., 2006. CD4⁺ T Cell responses are required for clearance of West Nile Virus from the central nervous system. *J. Virol.* 80, 12060–12069.
- Smithburn, K.C., Hughes, T.P., Burke, A.W., Paul, J.H., 1940. A neurotropic virus isolated from the blood of a native of Uganda. *Am. J. Trop. Med. Hyg.* 20, 471–492.
- Sodroski, J.G., 1999. HIV-1 entry inhibitors in the side pocket. *Cell* 99, 243–246.
- Solomon, T., Dung, N.M., Wills, B., Kneen, R., Gainsborough, M., Diet, T.V., Thuy, T.T., Loan, H.T., Khanh, V.C., Vaughn, D.W., White, N.J., Farrar, J.J., 2003. Interferon alpha-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. *Lancet* 361, 821–826.
- Sontheimer, E.J., 2005. Assembly and function of RNA silencing complexes. *Nat. Rev. Mol. Cell Biol.* 6, 127–138.
- Spruth, M., Stoiber, H., Kacani, L., Schonitzer, D., Dierich, M.P., 1999. Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. *AIDS Res. Hum. Retroviruses* 15, 533–543.
- Stadler, K., Allison, S.L., Schallig, J., Heinz, F.X., 1997. Proteolytic activation of tick-borne encephalitis virus by furin. *J. Virol.* 71, 8475–8481.
- Steele, C.R., Oppenheim, D.E., Hayday, A.C., 2000. Gamma(delta) T cells: non-classical ligands for non-classical cells. *Curr. Biol.* 10, R282–R285.
- Stein, D.A., Shi, P.Y., 2008. Nucleic acid-based inhibition of flavivirus infections. *Front. Biosci.* 13, 1385–1395.
- Sukupolvi-Petty, S., Purtha, W.E., Austin, S.K., Oliphant, T., Nybakken, G., Schlesinger, J.J., Roehrig, J.T., Gromowski, G.D., Barrett, A.D., Fremont, D.H., Diamond, M.S., 2007. Type- and sub-complex-specific neutralizing antibodies against domain III of dengue virus type-2 envelope protein recognize adjacent epitopes. *J. Virol.* 81, 12816–12826.
- Summerton, J., Stein, D., Huang, S.B., Matthews, P., Weller, D., Partridge, M., 1997. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. *Antisense Nucleic Acid Drug Dev.* 7, 63–70.
- Takhampanya, R., Ubol, S., Houg, H.S., Cameron, C.E., Padmanabhan, R., 2006. Inhibition of dengue virus replication by mycophenolic acid and ribavirin. *J. Gen. Virol.* 87, 1947–1952.
- Tesh, R.B., Arroyo, J., Travassos Da Rosa, A.P., Guzman, H., Xiao, S.Y., Monath, T.P., 2002. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. *Emerg. Infect. Dis.* 8, 1392–1397.
- Throsby, M., Geuijen, C., Goudsmit, J., Bakker, A.Q., Korimbocus, J., Kramer, R.A., Clijsters-van der Horst, M., de Jong, M., Jongeneelen, M., Thijssen, S., Smit, R., Visser, T.J., Bijl, N., Marissen, W.E., Loeb, B.J., Dille, B.J., Preiser, W., ter Meulen, J., de Kruif, J., 2006. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. *J. Virol.* 80, 6982–6992.
- Tobler, L.H., Bianco, C., Glynn, S.A., Schreiber, G.B., Dille, B.J., Prince, H.E., Lanciotti, R.S., Linnen, J.M., Gallarda, J., Shyamala, V., Smith, D., Kleinman, S.H., Busch, M.P., 2005. Detection of West Nile virus RNA and antibody in frozen plasma components from a voluntary market withdrawal during the 2002 peak epidemic. *Transfusion* 45, 480–486.
- Town, T., Bai, F., Wang, T., Kaplan, A.T., Qian, F., Montgomery, R.R., Anderson, J.F., Flavell, R.A., Fikrig, E., 2009. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. *Immunity* 30, 242–253.
- Town, T., Jeng, D., Alexopoulos, L., Tan, J., Flavell, R.A., 2006. Microglia recognize double-stranded RNA via TLR3. *J. Immunol.* 176, 3804–3812.
- Tsai, T.F., Popovici, F., Cernescu, C., Campbell, G.L., Nedelcu, N.I., 1998. West Nile encephalitis epidemic in southeastern Romania. *Lancet* 352, 767–771.
- Vargin, V.V., Semenov, B.F., 1986. Changes of natural killer cell activity in different mouse lines by acute and asymptomatic flavivirus infections. *Acta Virol.* 30, 303–308.
- Vazquez, S., Guzman, M.G., Guillen, G., Chinea, G., Perez, A.B., Pupo, M., Rodriguez, R., Reyes, O., Garay, H.E., Delgado, I., Garcia, G., Alvarez, M., 2002. Immune response to synthetic peptides of dengue prM protein. *Vaccine* 20, 1823–1830.
- Verma, S., Lo, Y., Chapagain, M., Lum, S., Kumar, M., Gurjav, U., Luo, H., Nakatsuka, A., Nerurkar, V.R., 2009. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: transmigration across the in vitro blood–brain barrier. *Virology* 385, 425–433.
- Vogt, M.R., Moesker, B., Goudsmit, J., Jongeneelen, M., Austin, S.K., Oliphant, T., Nelson, S., Pierson, T.C., Wilschut, J., Throsby, M., Diamond, M.S., 2009. Human monoclonal antibodies induced by natural infection against West Nile Virus neutralize at a post-attachment step. *J. Virol.* 83, 6494–6507.
- Voinnet, O., 2005. Induction and suppression of RNA silencing: insights from viral infections. *Nat. Rev. Genet.* 6, 206–220.
- Volk, D.E., Beasley, D.W., Kallick, D.A., Holbrook, M.R., Barrett, A.D., Gorenstein, D.G., 2004. Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. *J. Biol. Chem.* 279, 38755–38761.
- Wang, P., Dai, J., Bai, F., Kong, K.F., Wong, S.J., Montgomery, R.R., Madri, J.A., Fikrig, E., 2008a. Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. *J. Virol.* 82, 8978–8985.
- Wang, S., Welte, T., Fang, H., Chang, G.J., Born, W.K., O'Brien, R.L., Sun, B., Fujii, H., Kosuna, K., Wang, T., 2009. Oral administration of active hexose correlated compound enhances host resistance to West Nile encephalitis in mice. *J. Nutr.* 139, 598–602.
- Wang, S., Welte, T., McGargill, M., Town, T., Thompson, J., Anderson, J.F., Flavell, R.A., Fikrig, E., Hedrick, S.M., Wang, T., 2008b. Drak2 contributes to West Nile virus entry into the brain and lethal encephalitis. *J. Immunol.* 181, 2084–2091.
- Wang, T., Anderson, J.F., Magnarelli, L.A., Wong, S.J., Koski, R.A., Fikrig, E., 2001. Immunization of mice against West Nile virus with recombinant envelope protein. *J. Immunol.* 167, 5273–5277.
- Wang, T., Gao, Y., Scully, E., Davis, C.T., Anderson, J.F., Welte, T., Ledizet, M., Koski, R., Madri, J.A., Barrett, A., Yin, Z., Craft, J., Fikrig, E., 2006. Gamma delta T cells facilitate adaptive immunity against West Nile virus infection in mice. *J. Immunol.* 177, 1825–1832.
- Wang, T., Scully, E., Yin, Z., Kim, J.H., Wang, S., Yan, J., Mamula, M., Anderson, J.F., Craft, J., Fikrig, E., 2003a. IFN- γ -producing $\gamma\delta$ T cells help control murine West Nile virus infection. *J. Immunol.* 171, 2524–2531.
- Wang, T., Town, T., Alexopoulos, L., Anderson, J.F., Fikrig, E., Flavell, R.A., 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. *Nat. Med.* 10, 1366–1373.
- Wang, Y., Lobigs, M., Lee, E., Mullbacher, A., 2003b. CD8⁺ T cells mediate recovery and immunopathology in West Nile virus encephalitis. *J. Virol.* 77, 13323–13334.
- Waterhouse, P.M., Wang, M.B., Lough, T., 2001. Gene silencing as an adaptive defence against viruses. *Nature* 411, 834–842.
- Webb, H.E., Wight, D.G., Platt, G.S., Smith, C.E.G., 1968. Langat virus encephalitis in mice. I. The effect of the administration of specific antiserum. *J. Hyg.* 66, 343–354.
- Welsch, S., Miller, S., Romero-Brey, I., Merz, A., Bleck, C.K., Walther, P., Fuller, S.D., Antony, C., Krijnse-Locker, J., Bartenschlager, R., 2009. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. *Cell Host Microbe* 5, 365–375.

- Welte, T., Lamb, J., Anderson, J.F., Born, W.K., O'Brien, R.L., Wang, T., 2008. Role of two distinct gammadelta T cell subsets during West Nile virus infection. *FEMS Immunol. Med. Microbiol.* 53, 275–283.
- Whitby, K., Pierson, T.C., Geiss, B., Lane, K., Engle, M., Zhou, Y., Doms, R.W., Diamond, M.S., 2005. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. *J. Virol.* 79, 8698–8706.
- Wong, S.J., Boyle, R.H., Demarest, V.L., Woodmansee, A.N., Kramer, L.D., Li, H., Drebot, M., Koski, R.A., Fikrig, E., Martin, D.A., Shi, P.Y., 2003. Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. *J. Clin. Microbiol.* 41, 4217–4223.
- Wong, S.J., Demarest, V.L., Boyle, R.H., Wang, T., Ledizet, M., Kar, K., Kramer, L.D., Fikrig, E., Koski, R.A., 2004. Detection of human anti-flavivirus antibodies with a West Nile Virus recombinant antigen microsphere immunoassay. *J. Clin. Microbiol.* 42, 65–72.
- Wu, K.P., Wu, C.W., Tsao, Y.P., Kuo, T.W., Lou, Y.C., Lin, C.W., Wu, S.C., Cheng, J.W., 2003. Structural basis of a Flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese Encephalitis virus envelope protein. *J. Biol. Chem.* 278, 46007–46013.
- Wu, S.F., Lee, C.J., Liao, C.L., Dwek, R.A., Zitzmann, N., Lin, Y.L., 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. *J. Virol.* 76, 3596–3604.
- Wu, S.J., Grouard-Vogel, G., Sun, W., Mascola, J.R., Brachtel, E., Putvatana, R., Louder, M.K., Filgueira, L., Marovich, M.A., Wong, H.K., Blauvelt, A., Murphy, G.S., Robb, M.L., Innes, B.L., Birx, D.L., Hayes, C.G., Frankel, S.S., 2000. Human skin Langerhans cells are targets of dengue virus infection. *Nat. Med.* 6, 816–820.
- Xiao, S.Y., Guzman, H., Zhang, H., Travassos da Rosa, A.P., Tesh, R.B., 2001. West Nile virus infection in the golden hamster (*Mesocricetus auratus*): a model for West Nile encephalitis. *Emerg. Infect. Dis.* 7, 714–721.
- Yang, J.S., Ramanathan, M.P., Muthumani, K., Choo, A.Y., Jin, S.H., Yu, Q.C., Hwang, D.S., Choo, D.K., Lee, M.D., Dang, K., Tang, W., Kim, J.J., 2002. Induction of Inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. *Emerg. Infect. Dis.* 8, 1379–1384.
- Yang, M.R., Lee, S.R., Oh, W., Lee, E.W., Yeh, J.Y., Nah, J.J., Joo, Y.S., Shin, J., Lee, H.W., Pyo, S., Song, J., 2008a. West Nile virus capsid protein induces p53-mediated apoptosis via the sequestration of HDM2 to the nucleolus. *Cell Microbiol.* 10, 165–176.
- Yang, Y., Wu, C., Wu, J., Nerurkar, V.R., Yanagihara, R., Lu, Y., 2008b. Inhibition of West Nile Virus replication by retrovirus-delivered small interfering RNA in human neuroblastoma cells. *J. Med. Virol.* 80, 930–936.
- Young, J.K., Li, D., Abramowitz, M.C., Morrison, T.G., 1999. Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions. *J. Virol.* 73, 5945–5956.
- Zeitlin, L., Cone, R.A., Whaley, K.J., 1999. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases. *Emerg. Infect. Dis.* 5, 54–64.
- Zhang, B., Chan, Y.K., Lu, B., Diamond, M.S., Klein, R.S., 2008. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. *J. Immunol.* 180, 2641–2649.
- Zhang, S., Vogt, M.R., Oliphant, T., Engle, M., Bovshik, E.I., Diamond, M.S., Beasley, D.W. The development of resistance to passive therapy by a potentially neutralizing humanized West Nile virus monoclonal antibody. *J. Infect. Dis.*, in press.
- Zhang, W., Chipman, P.R., Corver, J., Johnson, P.R., Zhang, Y., Mukhopadhyay, S., Baker, T.S., Strauss, J.H., Rossmann, M.G., Kuhn, R.J., 2003a. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. *Nat. Struct. Biol.* 10, 907–912.
- Zhang, W., Wu, J., Li, Y., Li, F., Njoo, H., 2009. Rapid and accurate in vitro assays for detection of West Nile virus in blood and tissues. *Transfus. Med. Rev.* 23, 146–154.
- Zhang, Y., Corver, J., Chipman, P.R., Zhang, W., Pletnev, S.V., Sedlak, D., Baker, T.S., Strauss, J.H., Kuhn, R.J., Rossmann, M.G., 2003b. Structures of immature flavivirus particles. *Embo J.* 22, 2604–2613.
- Zhang, Y., Zhang, W., Ogata, S., Clements, D., Strauss, J.H., Baker, T.S., Kuhn, R.J., Rossmann, M.G., 2004. Conformational changes of the flavivirus E glycoprotein. *Structure (Camb.)* 12, 1607–1618.